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ABSTRACT

Colorectal cancer is the third leading cause of cancer-related mortality.
Much progress has been achieved in combating this disease with surgical resection and
chemotherapy in combination with targeted drugs. However, most metastatic patients
develop drug resistance so new modalities of treatment are needed.
Notch signaling plays a vital role in intestinal homeostasis, self-renewal, and cell
fate decisions during post-development and is activated in colorectal adenocarcinomas.
Under debate is its role in carcinomas and metastatic disease. In theory, blocking
Notch activation using gamma-secretase inhibitors (GSIs) may show efficacy alone or in
combination with chemotherapy in the treatment of colon cancer.
In Chapter Three, we tested the capacity for GSIs to synergize with oxaliplatin in
colon cancer cell lines and evaluated the underlying molecular mechanisms. GSI alone
had no effect on colon cancer cell lines. Surprisingly, we show that GSIs blocked
oxaliplatin-induced apoptosis through increased protein levels of the anti-apoptotic Bcl-2
proteins Mcl-1 and/or Bcl-xL. Restoration of apoptosis was achieved by blocking Mcl-1
and/or Bcl-xL with obatoclax (an anti-apoptotic Bcl-2 agonist) or siRNA. An unexpected
result was the induction of cell death with the combination of GSI and obatoclax.
In Chapter Four, we examined the mechanism of GSI + obatoclax-mediated cell
death. We found that apoptosis played a minimal role. Rather, we identified blockage
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of cytoprotective autophagy played a causative role. Interestingly, we also saw
autophagy induction in GSI-treated cells, which could explain the insensitivity of colon
cancer cells to GSI. When autophagy was blocked in GSI-treated cells, cells became
sensitive to GSI and cell death was elicited. The mechanism by which induction of
autophagy occurs in GSI- treated cells is an area for further research.
Overall, our work questions the validity of the use of GSIs in the treatment of
colorectal cancers. We show that GSIs may block apoptosis and induce cytoprotective
autophagy simultaneously, resulting in increased drug resistance and cellular survival.
Whether these two cellular survival processes occurs in patients needs to be examined
before GSIs can be utilized in a clinical setting. If so, these two hurdles must be
overcome.
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CHAPTER ONE: INTRODUCTION

Cancer
Cancer comprises of a diverse and complex range of diseases caused by both
intrinsic (such as germline or somatic mutations, epigenetics, and hormones) and
extrinsic (such as cigarette smoke, ionizing radiation, and chemical carcinogens)
factors. The lifetime risk of developing cancer is 1 in 2 for both men and women in the
United States, accounting for an estimated 1.6 million new cases per year (Siegel et al.
2013). One in 4 deaths is due to cancer, making it the seconding leading cause of
death following heart disease (Howlader et al. 2013). Cancer can originate at any site
in the body, with the lungs, prostate, breast, and colon leading the pack. The road to
cancer development is a multi-step and multi-lateral process involving multiple
molecular pathways within the cell that transforms a normal cell into a malignant one.
The classical “Hallmarks of Cancer” include self-sufficiency in growth signals,
insensitivity to anti-growth signals, cell-death evasion, limitless replicative potential,
angiogenesis, and tissue invasion and metastasis, with this list being recently updated
to also include reprogramming of metabolic pathways, immune system evasion,
chromosomal abnormalities and DNA instability, and inflammation (Hanahan et al.
2000; Hanahan et al. 2011). While substantial progress has been made in the
prevention and treatment of cancer, the heterogeneity and plasticity of cancer cells has
1

impeded effective long-term strategies to manage or ‘cure’ many cancer types.
Targeted molecular therapy, alone or in combination with conventional chemotherapy
and/or other targeted therapies, has therefore been the current focus of medical
research.

Colorectal Cancer
Colorectal cancer accounts for more than 50,000 deaths each year in the United
States and remains the third leading cause of cancer-related mortality (Siegel et al.
2013). While surgical resection remains the gold standard of treatment for localized
disease, chemotherapy combinations with oxaliplatin, irinotecan, 5-fluorouracil, the
VEGF inhibitor bevacizumab, and EGFR inhibitors have led to significant improvements
in survival at all stages (Saltz 2009; Garcia-Foncillas et al. 2010). However, most
metastatic colorectal cancer patients eventually develop drug resistance to current
therapies so new strategies are needed for treatment and improved survival of these
patients.

Colon Architecture
Normal human colon has millions of self-renewing crypts, each containing around
2000 cells (Cheng et al. 1984; Potten et al. 1992). The crypt is maintained by a small
population of stem cells located at or near the base of the crypt; they divide slowly and
gives rise to transit-amplifying progenitor cells (Figure 1). These progenitor cells have a
very limited capacity to self-renew; within three to four divisions they terminally
differentiate into one of the mature epithelial lineages – absorptive
2

colonocytes/enterocytes, hormone-secreting enteroendocrine cells, and mucusproducing goblet cells (Potten et al. 1997). The differentiated cells migrate towards the
surface of the colon where they die and are shed into the lumen. All the cells of the
crypt, except the stem cell, are regenerated every 5-7 days (Barker et al. 2008).

Figure 1: Architecture of the Colon Crypt
In the colon, stem cells are thought to reside at the base of the colon crypt and give rise
to transit-aplifying progenitor cells. These transit-amplifying cells then terminally
differentiate into either colonocytes, enteroendocrine cells, or goblet cells. Reprinted by
permission from Nature Publishing Group (McDonald et al. 2006).
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Figure 2: Sequence of Events to Colorectal (Adenoma:Carcinoma) Cancer
Mutations in the APC gene are considered to be an early event in colon carcinogenesis.
Subsequent activation of oncogenes and repression of tumor suppressor genes, along
with increasing genetic instability, leads to progression and development of
adenocarcinoma. Reprinted by permission from Nature Publishing Group (McDonald et
al. 2006).

Colorectal (Colon) Carcinogenesis
Dr. Bert Vogelstein introduced a multi-step model of colon carcinogenesis in
1988 (Figure 2). Mutations in the APC (adenomatous polyposis coli) gene are
considered to be one of the earliest events in this process, occurring in up to 80% of
sporadic colorectal carcinomas (Vogelstein et al. 1988). The APC tumor-suppressor
protein downregulates the Wnt/β-catenin pathway, leading to increased cell proliferation
and inhibition of cell death (He et al. 2004; Gregorieff et al. 2005). Further mutations in
K-RAS, SMADs, and TP53 can occur during colorectal cancer progression. More
recently, chromosomal instability (CIN) and microsatellite instability (MSI) have been
described as distinct molecular mechanisms that give rise to colorectal cancer, each
4

displaying unique molecular features. Other pathways that drive carcinogenesis include
Notch, TFG-β, EGFR, and PI3K signaling (Pritchard et al. 2011).

The Notch Pathway
The Notch pathway is an evolutionarily conserved pathway important in cell
differentiation, proliferation, apoptosis, cell fate decisions, and stem cell renewal during
development and cancer. The Notch receptor is a heterodimeric type 1 single-pass
transmembrane protein that undergoes a series of proteolytic cleavage steps to form a
mature receptor (Figure 3). There are four Notch family proteins (Notch1-4) that begin
as a ~300 kDa precursor protein. The protein is shuttled to the trans-Golgi
compartment where it is cleaved by furin-like convertases, generating N- and C-terminal
fragments (NTF and CTF), which are subsequently joined by noncovalent bonds
(Blaumueller et al. 1997; Logeat et al. 1998; Rand et al. 2000). The NTF also becomes
heavily glycosylated to ensure proper folding and facilitate ligand binding (Vodovar et al.
2008). The mature receptor is then exported to the cell surface. Notch signaling begins
with binding of the NTF to one of its five ligands (Jagged 1-2 and Delta-like 1, 3, and 4)
located on adjacent cells, allowing for exposure of the second cleavage site on the
extracellular portion of the CTF by TACE/ADAM metalloproteases (Brou et al. 2000;
Mumm et al. 2000). This generates a membrane-anchored activated Notch form
termed Notch extracellular truncation (NEXT). NEXT is then swiftly cleaved at a third
site by gamma-secretase, an intramembrane aspartyl protease complex, releasing the
Notch IntraCellular Domain (NICD) (Schroeter et al. 1998; De Strooper et al. 1999).
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Figure 3: Overview of Notch Receptor Synthesis and Signaling
The precursor Notch protein is cleaved by furin-like convertases in the trans-Golgi
compartment to produce an N-terminal extracellular fragment and a C-terminal
transmembrane fragment. These two fragments are joined through noncovalent linkage
to form the mature heterodimeric receptor and shuttled to the cell surface. Notch
signaling is initiated through binding of its receptor to its ligand located on an adjacent
cell, allowing for exposure of the second cleavage site by TACE/ADAM metalloprotease
followed by intramembranous cleavage at a third site by gamma-secretase. Cleavage
by gamma-secretase releases the Notch IntraCellular Domain (NICD). NICD
translocates to the nucleus, binds to the transcription factor CSL (CBF-1), displaces The
intracellular activated form of Notch, NICD, translocates to the nucleus and binds to
various corepressors, and recruits MAML-1 and p300/CBP to initiate transcription of
Notch target genes. Reprinted by permission from Elsevier (Fortini 2009).
6

The transcriptional factor CSL (CBF-1/suppressor of hairless/Lag-1), displacing various
co-repressors and recruiting MAML-1 (mastermind-like-1) and p300/CBP to induce
transcription (Tamura et al. 1995; Fryer et al. 2002; Wallberg et al. 2002). Notch target
genes include the HES (hairy/enhancer of split) and HEY family members, c-myc, p21,
and cyclin D1, to name a few (Jarriault et al. 1995; Borggrefe et al. 2009).

Gamma-Secretase Complex
Gamma-secretase is a multiprotein transmembrane complex consisting of at
least 4 core components: presenilin (PSEN), Pen-2, nicastrin (NCT), and Aph-1 (Figure
4). The complex catalyzes the intramembranous cleavage of type I transmembrane
proteins such as APP (amyloid precursor protein, implicated in the development of
Alzheimer’s Disease), Notch, E-cadherin, ErbB4, CD44, and c-Met (for review, see
(Haapasalo et al. 2011)). Presenilin1, an aspartyl type protease, is the catalytic domain
of gamma-secretase and contains nine transmembrane domains (Wolfe et al. 1999;
Laudon et al. 2005). Nicastrin is another type I integral membrane protein (Yu et al.
2000). Aph-1 has 7 transmembrane domains while Pen-2 has two (Francis et al. 2002;
Goutte et al. 2002). All four proteins are necessary and sufficient for gamma-secretase
activity (Kimberly et al. 2003; Takasugi et al. 2003). Nicastrin is essential for stability of
the complex; NCT-null mouse fibroblasts retain on 50% gamma-secretase activity
compared to wildtype but the trimeric complex is highly unstable (Zhao et al. 2010).
Aph-1 is also important to regulate stability (LaVoie et al. 2003). Pen-2 also increases
stability of the complex and may contribute to the proteolytic activity of the complex
(Bammens et al. 2011). More than 50 additional proteins are thought to associate with
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gamma-secretase, regulating its activity, subcellular localization, and substrate
specificity (Chen et al. 2002; McCarthy et al. 2009)

Figure 4: Schematic of Gamma-secretase Assembly and Activation
The gamma-secretase complex consists of at least four core proteins: Presenilin
(PSEN), Pen-2, Nicastrin (NCT), and Aph-1. Presenilin is the catalytic domain of the
complex but is highly unstable and rapidly degraded. Binding of NCT and Aph-1 to
Presenilin help stabilize the complex. Finally, binding of Pen-2, while also potentially
increasing stability, contributes to the proteolytic activity of the mature complex.
Reprinted by permission from Nature Publishing Group (Takasugi et al. 2003).

Notch Signaling: Oncogenic and Tumor-Suppressive
Aberrant activation of Notch signaling has been implicated in a variety of solid
tumors, including breast (Reedijk et al. 2005; Stylianou et al. 2006), melanoma (Bedogni
et al. 2008), ovarian (Wang et al. 2010), and prostate (Santagata et al. 2004; Wang et
al. 2010). It was first linked to T-cell acute lymphoblastic leukemia (T-ALL), where
8

>50% of tumors harbored activating mutations within Notch1 (Ellisen et al. 1991; Weng
et al. 2004). In contrast, reduced Notch signaling has been implicated in HPV-positive
cervical cancer (Talora et al. 2002), neuroendocrine tumors (Kunnimalaiyaan et al.
2007), small cell lung cancer (Sriuranpong et al. 2001), hepatocellular carcinoma (Qi et
al. 2003), and skin squamous cell carcinoma (Lefort et al. 2007). Indeed, the use of
gamma-secretase inhibitors in clinical trials for Alzheimer’s Disease (the amyloid
precursor protein – APP –implicated in this disease is a gamma-secretase target)
showed an increase risk of skin cancer development (McKee); decreased gammasecretase activity is also associated with increased skin cancer occurrence in mice (Li
et al. 2007). Therefore, the biological outcome/function of Notch signaling as oncogenic
or tumor-suppressive is highly cell context specific (reviewed in (Radtke et al. 2003;
Leong et al. 2006)).

Notch Signaling in Normal Colon
The Notch pathway is one signaling pathway that plays a major role in
homeostasis of the colon crypt compartment (Radtke et al. 2005). One function is to
maintain the intestinal stem/progenitor cells; these are the cells that express Notch
receptors and downstream target genes (Schroder et al. 2002; Sander et al. 2004).
Transgenic mice expressing NICD under the control of an intestine-specific Villin
promoter exhibited significantly increased proliferation in crypt cells, impaired
differentiation into goblet and enteroendocrine cells, and upregulated Hes1 (Fre et al.
2005). Deletion of CSL by cre-mediated recombination in the intestinal epithelium of
mice revealed a massive differentiation of the proliferative transit-amplifying cells into
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goblet cells; similar phenotypic results were obtained by blocking Notch signaling with a
gamma-secretase inhibitor in mice with normal colons and in adenomas arising in
ApcMin mice (van Es et al. 2005). These findings are consistent with observations in
HES1-null mice and rats treated with gamma-secretase inhibitors showing goblet cells
metaplasia (Jensen et al. 2000; Milano et al. 2004).

Aberrant Activation of Notch Signaling in Colon Cancer
The Notch pathway has been implicated in colon cancer tumorogenesis.
Colorectal cancer tumors in humans show higher expression of NOTCH1, JAGGED
ligands, and HES1 compared to normal by in situ hybridization and qPCR (Reedijk et al.
2008; Qiao et al. 2009). Transgenic expression of NICD in ApcMin mice, which form
multiple adenomas (but do not progress into carcinoma), show increased number of
adenomas, suggesting that Notch signaling may play a role in initiation but not
progression of intestinal tumors (Fre et al. 2009). This group also showed elevated
levels of Notch-1 and Hes-1 in adenomas compared to carcinomas in a small cohort of
human patients. These finding are consistent with other studies in humans showing
high Notch signaling in adenomas and early-stage colon carcinomas but low in laterstage, advanced and metastatic colon carcinomas (Reedijk et al. 2008; Rodilla et al.
2009). The molecular mechanisms underlying this distinction remain unclear.

Apoptosis
Apoptosis is an evolutionarily conserved multi-step form of type I programmed
cell death that culminates in the self-destruction of a cell. This process is important in
10

normal development, aging, and tissue homeostasis by removing damaged or
redundant cells. For example, cells in the bone marrow and intestine undergo
apoptosis to make way for new cells every day. The deregulation of apoptosis is
associated with disease: increased apoptosis in neurodegenerative disorder and
inhibition of apoptosis in cancer, for example (Thompson 1995).
The morphological and biochemical features that characterize apoptosis include
cell shrinkage, membrane blebbing, chromosome condensation, nuclear fragmentation,
mitochondrial membrane disruption, activation of caspases, and exposure of
phosphatidylserine (PS) on the outer leaflet of the plasma membrane (Kerr et al. 1972;
Martin et al. 1995; Saraste et al. 2000). The resultant apoptotic cell is removed by
phagocytosis, providing the engulfing cell with recyclable cellular material while avoiding
inflammation.
Apoptosis can be triggered by two pathways: the extrinsic pathway or the intrinsic
pathway. The extrinsic pathway of apoptosis is activated upon binding of a specific
ligand to death receptors. The intrinsic pathway is activated by cellular stress and
involves the mitochondria. Apoptosis is tightly regulated and leads to the execution of
step-wise caspase activation. Caspases, cysteinyl aspartate-specific proteases, are
synthesized as inactive precursors known as procaspases and are activated upon
cleavage. They can be separated into two functional groups: initiator caspases
(caspase-2, -8, -9, -10) and effector caspases (caspases-3, -6, -7) (Cohen 1997).
Active caspases can then cleave other caspases to amplify the signal or cleave other
proteins, resulting in the morphological and biochemical features of apoptosis (Enari et
al. 1998; Coleman et al. 2001; Taylor et al. 2008).
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Figure 5: The Intrinsic and Extrinsic Pathways of Apoptosis
The extrinsic apoptotic pathway is activated upon binding of a specific ligand to death
receptors and subsequent recruitment of cytoplasmic adaptor proteins and initiator
procaspase-8 and/or -10. The initiator procaspases are cleaved to produce mature,
active caspase-8 and/or -10 that, in turn, cleave and activate effector caspase-3, -6,
and/or -7. The intrinsic pathway is initiated by extra- or intracellular stress, leading to
activation of Bax and/or Bak at the mitochondria and subsequent cytochrome c release.
Cytochrome c forms a complex with Apaf-1 and caspase-9 and this complex cleaves
and activates effector caspase-3, -6, and/or -7. Reprinted by permission from Nature
Publishing Group (Ashkenazi 2008).
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The Extrinsic Apoptotic Pathway
The extrinsic, or receptor-mediated, pathway involves activation of the tumor
necrosis factor (TNF) family member receptors by their extracellular ligands (Figure 5).
These receptors, often referred to as death receptors, all contain cysteine-rich
extracellular domains responsible for ligand binding and a cytoplasmic death domain
(DD). Members include TRAIL, FasL, TNFR1-2, and DN3-5 (Locksley et al. 2001).
Ligand binding initiates receptor trimerization and activation, leading to the recruitment
of cytoplasmic adaptor proteins such as FADD (Fas-associated death domain) or
TRADD (TNF-associated death domain) to the DD of the receptor (Ashkenazi et al.
1998). FADD also contains a death effector domain (DED) that recruits DED-containing
initiator caspase-8 and/or caspase-10. The resultant complex formed is termed deathinducing signaling complex (DISC) and is responsible for proteolytic processing and
activation of the initiator caspases leading to further cleaving and activation of the
effector caspases (Ashkenazi 2002). The apoptotic signal can be further amplified by
cleavage of BID by caspase-8 into a truncated form (tBID). This tBID protein
translocates into the mitochondria and interacts with Bak and Bax to activate the
intrinsic apoptotic pathway (Yin 2000).

The Intrinsic Apoptotic Pathway
The intrinsic, or mitochondrial, pathway is activated by extracellular and
intercellular stresses, including growth factor withdrawal, oxidative stress, hypoxia,
radiation, and chemotherapy (Figure 5).
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The members of Bcl-2 family tightly regulate apoptosis through the intrinsic
pathway. They can be divided into two classes: inhibitors of apoptosis and promoters of
apoptosis. Anti-apoptotic Bcl-2 members include Bcl-2, Bcl-xL, Mcl-1, and Bcl-w and
share structural similarity within all four of their Bcl-2 homology (BH) domains. Proapoptotic Bcl-2 members can be further subdivided into multi-domain proteins, like Bax,
Bak, and Bok, and into BH-3 only proteins, like Puma, Noxa, Bim, Bad, and Bid (Petros
et al. 2004). The anti-apoptotic members inhibit apoptosis by inhibiting Bax and Bak,
thereby maintaining mitochondrial integrity. The BH-3 only proteins act as stress
sensors; two models have been proposed to explain how they promote apoptosis. First,
in the displacement model, the BH3-only proteins bind to anti-apoptotic Bcl-2 family
members, releasing them from Bax and Bak. In the second model, the BH-3 only
proteins directly activate the multi-domain, pro-apoptotic proteins Bax and Bak (Strasser
2005; Shamas-Din et al. 2011).
Once Bax and Bak are dissociated from anti-apoptotic Bcl-2 proteins, they
undergo a conformational change, translocate to the mitochondria, and oligomerize to
form a pore (Hsu et al. 1998; Lalier et al. 2007). This activation and subsequent pore
formation is required for mitochondrial outer membrane permeabilization (MOMP) and
results in the release of cytochrome c (and/or other apoptogenic proteins AIF,
endonuclease G, HtrA2/Omi, and Smac/Diablo) into the cytoplasm. There, cytochrome
c binds to Apaf-1, causing Apaf-1 oligomerization and recruitment of procaspase-9
(forming the apoptosome). Procaspase-9 clustering in the apoptosome results in its
cleavage to an activated form and subsequent cleavage of effector caspases.
Smac/Diablo and HtrA2/Omi bind to inhibitors of apoptosis (IAP) proteins, such as XIAP
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and cIAP, preventing their inhibition of effector caspases; AIF and endonuclease G
participate in DNA fragmentation. Initiation of the intrinsic apoptotic pathway is
therefore a delicate balance between pro- and anti-apoptotic factors (Shore et al. 2005).

Autophagy
Autophagy is an evolutionary conserved cellular pathway responsible for the
degradation and recycling of cellular material and organelles. Autophagy plays a role in
stress responses (including nutrient deprivation, growth factor withdrawal, hypoxia, and
chemotherapy) to promote survival, in cellular homeostasis to remove misfolded or
aggregated proteins and damaged organelles, and during host-defense to degrade
intracellular pathogens (Moreau et al. 2010). Three distinct forms of autophagy have
been described: macroautophagy, microautophagy, and chaperone-mediated
autophagy.
Autophagy plays a dual role in carcinogenesis. On one hand, it’s believed to play
a tumor suppressive role to limit tumor initiation. However, once neoplastic lesions
have been established, autophagy instead facilitates tumor progression and may be
critical for continued growth and sustained cellular metabolism. Autophagy is also
induced in response to chemotherapy to limit drug efficacy. Aberrant control of
autophagy is now considered to be another hallmark of cancer (Levine et al. 2008;
Kimmelman 2011).
Upon autophagy induction, a small vesicular sac called the isolation membrane
or phagophore elongates and subsequently encloses a portion of the cytoplasm. This
results in the formation of a double-membrane structure, termed the autophagosome.
15

The autophagosome matures when the outer membrane fuses with a lysosome (to form
the autolysosome), leading to the degradation of the enclosed materials together with
the inner autophagosomal membrane by lysosomal hydrolases. Amino acids and other
small molecules that are generated by autophagic degradation are delivered back to the
cytoplasm for recycling or energy production (Figure 6)(Yang et al. 2010).

Figure 6: The Process of Autophagy
Upon activation of autophagy by starvation or growth factor deprivation, for example,
cytoplasmic material becomes enclosed in a double-membrane structure termed the
autophagosome. The lysosome fuses with the autophagosome and leads to the
degradation of the enclosed cytoplasmic material. The resultant amino acids and other
small molecules generated can be used for energy-production or recycling. Reprinted
by permission from American Society of Clinical Investigation (Levine et al. 2005).
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Figure 7: The Core Molecular Machinery of Autophagy
There are three basic steps leading to autophagosome formation: initiation, vesicle
nucleation, and vesicle elongation and closure. Initiation begins when mTOR is
inactivated, allowing for the formation of the ULK1 complex. Vesicle nucleation begins
by the formation of the Beclin1-Vsp34 PI3K-Atg14L-Vsp15 complex. Vesicle elongation
and closure follows via two conjugation systems: Atg12 and LC3. They lead to the
conjugation of phosphatidylethanolamine (PE) to LC3-1, forming the autophagic vesicleassociated form (LC3-II). Reprinted by permission from Elsevier (Rautou et al. 2010).
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Core Molecular Machinery of Autophagy
As mentioned earlier, autophagy occurs at basal, constitutive levels in many cells
and is upregulated under physiological stress. The initiation of autophagy occurs mainly
through downregulation of mTOR (target of rapamycin) signaling and the Vps34 (a class
III phosphatidylinositol-3-kinase (PI3K)) – Atg6/Beclin-1 complex (Yang et al. 2010).

ATG genes
The basic molecular machinery of autophagy involves many ATG (autophagy
associated proteins) genes. They were first identified in yeast and show strong
evolutionary conservation from yeast to humans. The Atg proteins regulate the entire
process of autophagy initiation, maturation, and degradation of substrates. They are
divided into four core subgroups: 1) The Atg1/unk-51-like kinase (ULK1), 2)
Vsp34/Beclin-1 (Atg6), 3) two ubiquitin-like proteins (Atg12 and Atg8/LC3) conjugation
complexes, and 4) two transmembrane protein, Atg9 and VMP1 (vacuole membrane
protein 1) (Figure 7).
Atg1 exists in a complex with Atg13 and Atg7. Atg13 is phosphorylated by
mTOR signaling to modulate complex formation. Initiation begins when mTOR
becomes inactivated; Atg13 becomes dephosphorylated and increases Atg1-Atg7Atg13 complex formation, initiating autophagy. Vesicle nucleation begins by formation
of the autophagy-specific Vsp34-Beclin-1-Atg14L-Vsp15 complex. Vsp15 (vacuolar
sorting protein 15) (the yeast homologue of mammalian p150) is a protein kinase that
activates Vsp34. Vsp34 is a lipid kinase that generates phosphatidylinositol (3)phosphate (PtdIns(3)P) at the PAS (perivacuolar sites known as phagophore assembly
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sites) to allow recruitment of other Atg proteins. Agt14L is thought to direct the complex
to the phagophore and also initiate recruitment of other Atg proteins (Yang et al. 2010).
The nucleation step can be blocked by treatment with the PI3K inhibitor 3-MA (3methyladenine).
The two ubiquitin-like conjugation systems, Atg12-Atg5 and Atg8/LC3phosphatidylethanolamine (PE), regulate the elongation and expansion of
autophagosome formation. Atg7 and Atg10 (E1 and E2-like enzymes, respectively),
conjugate Atg12 to Atg5. The Atg12-Atg5 complex non-covalently interacts with
Atg16L. The second system involves cleavage of Atg8/LC3 (microtubule-associated
protein light chain 3) at its C terminus by Atg4. This generates the cleavage product
LC3-I, a cytosolic protein with a C-terminal glycine reside. PE is conjugated to the
glycine residue in a reaction that requires Atg7 and Atg3 (an E2-like enzyme). This
lipidated form of LC3 (LC3-II) is attached to both the outer and inner phagophore
membrane. Removal of LC3-II from the outer membrane of the autophagosome
facilitates its fusion to the lysosome (Yang et al. 2009; Yang et al. 2010). Upon
completion, LC3-II is degraded within the autolysosome. Monitoring of LC3-II levels is
one of the best markers to assess autophagic flux (Rubinsztein et al. 2009).
Mammalian Atg9 and VMP1 are two transmembrane proteins required for the
biogenesis of autophagosomes and recruitment of the Vsp34-Beclin1-Atg14L-Vsp15
complex to the phagophore, respectively. Atg9 shuttles between the trans-Golgi
network and late endosomes and peripheral sites. This shuttling is cycling of Atg9
localization is thought to contribute to the delivery of membranes to the forming
autophagosome (Yang et al. 2010).
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CHAPTER TWO: MATERIALS AND METHODS

Cell Lines and Chemicals
The human colorectal cancer cell lines HCT-116, HCT-15, HT-29, and Colo205
were obtained from NCI; SW480 was obtained from ATCC. All cell lines were grown in
RPMI 1640 supplemented with 10% FBS and L-glutamine and grown in a 37°C
humidified camber 5% CO2. Cells were maintained for no more than 30 passages after
thawing and tested as mycoplasma-free. HCT-116 and SW480 cell lines were
authenticated using short tandem repeat (STR) DNA typing according to ATCC’s
“Authentication of Human Cell Lines: Standardization of STR Profiling” (2012).
Oxaliplatin (Sigma) was suspended in 5% dextrose. The gamma-secretase
inhibitors MRK-003 (a generous gift from Merck Inc), DAPT (N-[N-(3,5difluorophenacetyl-L-alanyl)-S-phenylglycine]-t-butyl ester; Santa Cruz), GSI-XII
(Calbiochem), and GSI-XX (DBZ; Calbiochem) and the Bcl-2 inhibitor obatoclax (GX15070; Selleck) were suspended in DMSO. 3-MA (Santa Cruz) was suspended in water
and dissolved by heating at 100°C. Aliquots were stored at -20°C and reheated before
use. Bafilomycin A1 and z-VAD-FMK were purchased from Santa Cruz. Propidium
iodide and acridine orange were purchased from Sigma.
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Apoptosis Assays via Flow Cytometry
Apoptosis was measured by flow cytometry by detecting activated Caspase-3.
Cleaved Caspase-3 was measured using the Active Caspase3-FITC Apoptosis Assay
Kit (BD# 550480) according to the manufacturer’s protocol. Briefly, floating and
adherent cells were collected, washed in PBS, and fixed in Cytofix/Cytoperm buffer for
20 minutes on ice. Cells were then washed in Perm/Wash buffer and incubated with
Cleaved caspase3-FITC antibody for 30 minutes at room temperature. Data were
acquired on a FACS Scan or Calibur and analyzed with FlowJo software.
Apoptosis was also measured by AnnexinV-FITC (or AnnexinV-APC) (BD#
556420 or 550475) and 7-AAD staining according to the manufacturer’s protocol.
Adherent and non-adherent cells were collected and incubated in 1X Annexin-V Binding
Buffer (10mM Hepes pH 7.4, 150mM NaCl, 2.5nM CaCl2) with AnnexinV-FITC (or
AnnexinV-APC) and 7-AAD for 15 minutes at room temperature. Data were acquired
on a FACS Scan or Calibur and analyzed with FlowJo software. Dot plots with the
percentages of each quadrant were reported for each sample.
Apoptosis was also measured by Propidium iodide (PI) staining for cell viability.
Cells were harvested by trypsinization and washed with PBS. Cells were suspended in
2 µg/ml PI in PBS and kept on ice. Data were acquired on a FACS Scan or Calibur and
analyzed with FlowJo software.

Western Blotting
Cell pellets were lysed in standard RIPA buffer (50 mM Tris pH 7.4, 150 mM
NaCl, 1% Igepal CA-630, 0.5% sodium deoxycholate, and 0.1% SDS) containing
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protease and phosphatase inhibitors – 1 µg/ml each of aprotin, leupeptin, and pepstatin
and 1 mM each of sodium fluoride, sodium vanadate, phenylmethylsulfonyl fluoride, and
sodium pyrophosphate - for 30 minutes on ice. Cell extracts were clarified by
centrifugation at 15,000g for 10 minutes at 4°C. Protein concentration was determined
via the Bradford Assay and lysates were mixed 1:1 in 2X Laemmeli Sample Buffer and
heated at 95°C for 5 minutes. 30 µg of protein was resolved onto SDS-PAGE gels and
transferred onto PVDF membranes. Membranes were blocked in 1X TBST (Tris
buffered saline with 0.05% Tween-20) supplemented with 5% milk and primary
antibodies were incubated overnight at 4°C in 1% BSA or 5% milk dissolved in TBST.
Membranes were washed and incubated with peroxidase-conjugated anti-mouse or
anti-rabbit IgG secondary antibodies (Jackson ImmunoReasearch Laboratories). The
signals were visualized using SuperSignal West Pico Chemiluminescent detection
reagent (Pierce/ThermoScientific).

Primary Antibodies
The primary antibodies used for western blot were: rabbit anti-Mcl-1 (#5453),
rabbit anti-Bcl-xL (#2764), rabbit anti-PARP (#9542), rabbit anti-LC3A/B (#4599); rabbit
anti-Atg5 (#8540), and rabbit anti-Beclin1 (#3495) from Cell Signaling; mouse anti-βactin (#A5441) from Sigma; and mouse anti-p62 (#sc-28359) from Santa Cruz.

Cytochrome C Release
Adherent and non-adherent cells were harvested by scrapping and pelleted by
centrifugation. For preparation of cytosolic extracts, the cell pellet was immediately
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suspended in a cytochrome c permeabilization buffer (20 mM Hepes pH 7.5, 10 mM
KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 250 mM Sucrose)
containing 200 µg/ml Digitonin (Sigma# D141) supplemented with protease and
phosphatase inhibitors (see above in Western blotting) and incubated on ice for 5
minutes. Lysates were clarified by centrifugation at 1000g for 5 minutes at 4°C to
remove unlysed cells, cell debris and nuclei. The supernatant transferred to a new tube
and centrifuged at 20,000xg for 20 minutes at 4°C to remove mitochondria and any
remaining debris. The supernatant was transferred to a new tube and 20-30 µg of
protein was subjected to western blot analysis using anti-cytochrome c (BD# 556433)
antibody. An anti-COX IV (Cell Signaling# 4580) antibody was used as a control to
measure mitochondrial contamination of cytosolic extracts.

Cell Survival and Colony Formation Assays
Short-term cell survival was measured by MTT assay. Cells were seeded into
96-well plates in quadruplicate and drug treated the next day for 48 hours. MTT ((3(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma# M2128) was added
at a final concentration of 0.5 µg/uL per well and incubated for 3-4 hours in a humidified
chamber at 37°C in the dark. The plate was centrifuged, supernatant aspirated, 100 µL
/ well of DMSO added, and the absorbance measured at 540 nm. Data were
normalized relative to untreated controls, which were taken as 100% survival.
Colony / foci formation assays were used to assess long-term cell survival. Cells
were seeded into 12-well plates, allowed to attach overnight, and drug treated for 24
hours. Attached cells were then trypsinized, counted, and 1000 cells were plated in
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triplicate in 6-well plates and allowed to grow for 8 or 12 days. Cells were fixed with 4%
paraformaldehyde for 15 minutes with 0.1% crystal violet.

Cell Cycle Analysis
Adherent and non-adherent cells were collected, fixed in ice-cold 70% ethanol,
and kept at 4°C overnight. Cells were then stained with 20 µg/ml propidium iodine, 200
µg/ml RNase A, and 0.1% Triton X-100 in PBS for 30 minutes in the dark at room
temperature. Data was acquired on a FACS Scan or Calibur and analyzed with ModFit
software.

Activation of Bax and Bak
Cell pellets were lysed in CHAPS lysis buffer (1% CHAPS, 150 mM NaCl, 1 mM
Hepes pH7.4) containing protease and phosphatase inhibitors (see above for details)
for one hour on ice. Lysates were centrifuged and protein concentration was
determined by Bradford assay. 500 µg of protein was precleared with 20 µL of antiMouse IgG (whole molecule)-Agarose beads (Sigma# A6531) for one hour at 4°C with
rotation. The beads were pelleted and the supernatant was transferred to a new tube.
Activated Bax or Bak was immunoprecipitated with 2 µg of anti-Bax 6A7 (Sigma#
B8429) or anti-Bak Ab-1 (Calbiochem# AM03) antibodies and 20 µL of anti-Mouse IgGAgarose beads and incubated overnight at 4°C with rotation. The beads were pelleted
and washed three times in CHAPS lysis buffer before being subjected to western blot
analysis with rabbit anti-Bax (N-20, #sc-493) and rabbit anti-Bak (G-23, #sc-832),
respectively (Santa Cruz).
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RNA Interference
Small interfering RNA (siRNA) for Mcl-1 (#sc-35877), Bcl-xL (#43630), and
Control-A (#sc-37007) was purchased from Santa Cruz; Signalsilence siRNA for Atg5
(#6345), Beclin-1 (#6222) and Control (#6568) were purchased from Cell Signaling.
Cells were transfected with RNAiMax (Invitrogen) with a reverse transfection protocol
according to the manufacturer’s protocol. Briefly, siRNA and RNAiMax were incubated
in serum-free RPMI 1640 for at least 20 minutes at room temperature. After siRNA:
RNAiMax complexes were allowed to form, diluted cells in full serum media (RPMI 1640
+ 10% FBS) were added and the mixture plated out.
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CHAPTER THREE: GAMMA-SECRETASE INHIBITION ATTENUATES
OXALIPLATIN-INDUCED APOPTOSIS THROUGH INCREASED MCL-1 AND/OR
BCL-XL IN HUMAN COLON CANCER CELLS

Note to Reader
These results have been previously published (Timme et al., 2013) and are
utilized with permission of the publisher.

Abstract
The Notch signaling pathway plays a significant role in differentiation,
proliferation, apoptosis, and stem cell processes. It is essential for maintenance of the
normal colon crypt and has been implicated in colorectal cancer oncogenesis.
Downregulation of the Notch pathway through gamma-secretase inhibitors (GSIs) has
been shown to induce apoptosis and enhance response to chemotherapy in a variety of
malignancies. In this study, we analyzed the effect of MRK-003 (Merck), a potent
inhibitor of gamma-secretase, on oxaliplatin-induced apoptosis in colon cancer.
Unexpectedly, gamma-secretase inhibition reduced oxaliplatin-induced apoptosis while
GSI treatment alone was shown to have no effect on growth or apoptosis. We
determined that the underlying mechanism of action involved an increase in protein
levels of the anti-apoptotic Bcl-2 family members Mcl-1 and/or Bcl-xL, which resulted in
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reduced Bax and Bak activation. Blocking of Mcl-1 and/or Bcl-xL through siRNA or the
small molecule inhibitor obatoclax restored the apoptotic potential of cells treated with
both oxaliplatin and MRK-003. Moreover, obatoclax synergized with MRK-003 alone to
induce apoptosis. Our findings warrant caution when treating colon cancer with the
combination of GSIs and chemotherapy, whereas other drug combinations, such as
GSIs plus obatoclax, should be explored.

Results
Gamma-Secretase Inhibitors Attenuate Chemotherapy-induced Apoptosis of Colon
Cancer Cells
Inhibition of gamma-secretase has shown antitumor effects in a variety of
cancers in vitro and is thus considered an attractive pharmacological target. Pre-clinical
reports using cancer cell lines, patient samples in vitro, and in vivo mouse models on
the activity of MRK-003, a potent and selective GSI, have reported Notch pathway
inhibition and antitumor activity in multiple myeloma (Ramakrishnan et al. 2012), NonHodgkin’s leukemia (Ramakrishnan et al. 2012), T-cell acute lymphoblastic leukemia
(Lewis et al. 2007), breast cancer (Grudzien et al. 2010), pancreatic cancer (Plentz et
al. 2009; Vo et al. 2011), lung cancer (Konishi et al. 2007), and glioblastoma (Chen et
al. 2010).
Oxaliplatin is the first line of chemotherapy for colon cancer. We hypothesized
that combining oxaliplatin with gamma-secretase inhibitors would enhance
chemosensitivity in colon cancer cell lines, as others have shown using alternative
gamma-secretase inhibitors (Akiyoshi et al. 2008; Aleksic et al. 2008; Meng et al. 2009).
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Figure 8: Gamma-secretase Inhibition Attenuates Oxaliplatin-induced Apoptosis
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480)
oxaliplatin (Oxa) for 48 hours in the absence or presence of 10 µM (HCT-116) or 5 µM
(SW480) MRK-003 (GSI). Apoptosis rates were measure by flow cytometry following
Annexin-V/7-AAD staining (A) and active caspase-3 labeling (B). (C) Apoptosis rates
were measured by flow cytometry following active caspase-3 reactivity. Represented
data are mean +/- SEM of three independent experiments.
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To explore the role of gamma-secretase inhibition on oxaliplatin-induced
apoptosis, two colon cancer cell lines – HCT-116 and SW480 – were treated with
oxaliplatin in the absence or presence of MRK-003 (Merck, Inc), a potent gammasecretase inhibitor. The doses of MRK-003 used (10 µM for HCT-116 and 5 µM for
SW480) were determined, after dose response experiments, to be the maximum
dosage with no quantifiable toxicity (data not shown). Apoptosis was measured by flow
cytometry using either Annexin-V with 7-AAD double staining or measuring active
caspase-3. Annexin-V binds to the membrane phospholipid phosphatidylserine (PS)
upon exposure to the external cellular environment in apoptotic cells while 7-AAD is a
vital dye that is excluded from cells with an intact plasma membrane. The combination
of oxaliplatin and MRK-003 resulted in a reduction in apoptosis by at least 50% as
measured by either Annexin-V & 7-AAD positivity (Figure 8a) or activated caspase-3
(Figure 8b) in both cell lines compared to oxaliplatin alone.
To confirm that the results were likely due to gamma-secretase inhibition and not
an off target effect of MRK-003, the effect of alternative gamma-secretase inhibitors on
apoptosis of oxaliplatin treated cells were repeated using DAPT, GSI-XII, and GSI-XX
(DBZ), widely used and commercially available GSIs that are structurally distinct from
MRK-003. Both cell lines treated with DAPT and GSI-XX showed apoptosis rates
approximately half that of oxaliplatin-treated cells (Figure 9a,c). The gamma-secretase
inhibitor GSI-XII showed a slight decrease in oxaliplatin-induced apoptosis in SW480
but a slight induction was observed in HCT-116 (Figure 9b). MRK-003, DAPT, GSI-XII,
or GSI-XX alone did not induce apoptosis in either HCT-116 or SW480.
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Figure 9: Effects of Alternative GSIs on HCT-116 and SW480 Colon Cancer Cell
Lines
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480)
oxaliplatin (Oxa) for 48 hours in the absence or presence of 25 µM DAPT (A), 5 µM
(HCT-116) or 10 µM (SW480) GSI-XII (B), or 2 µM GSI-XX (C). Apoptosis rates were
measured by flow cytometry following active caspase-3 reactivity. Represented data
are mean +/- SEM of two independent experiments.
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We further tested the effect of MRK-003 on oxaliplatin-induced apoptosis in three
additional colon cancer cell lines to determine whether the reduction in apoptosis was
cell line specific. We found greater than 50% reduction of apoptosis in oxaliplatintreated HT-29, HCT-15, and Colo205 cells in the presence of MRK-003 (Figure 10).

Figure 10: Effects of MRK-003 on Oxaliplatin-Induced Apoptosis in HT-29, HCT-15,
and Colo205 Colon Cancer Cell Lines
HT-29, HCT-15, and Colo205 were treated with either 30 (HCT-15) or 50 µM (HT-29
and Colo205) Oxa in the absence or presence of 5 µM (HT-29) or 10 µM MRK-003
(HCT-15 and Colo205) for 48 hours. Apoptosis rates were measured by flow cytometry
following active caspase-3 reactivity. Represented data are mean +/- SEM of at least
two independent experiments
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Figure 11: Gamma-secretase Inhibition Attenuates Irinotecan- and Etoposideinduced Apoptosis
HCT-116 and SW480 cells were treated with either 50 µM Etoposide or 50 µM
Irinotecan in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-003
for 48 hours. Apoptosis rates were measured by flow cytometry following active
caspase-3 reactivity. Represented data are mean +/- SEM of two independent
experiments.
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To test if the attenuation of apoptosis was specific to oxaliplatin, we assessed the
effects of gamma-secretase inhibition with either irinotecan or etoposide. Again, we
observed a reduction of apoptosis in HCT-116 with MRK-003 in combination with either
irinotecan or etoposide; no difference in apoptosis was observed in SW480 (Figure 11).
Taken together, these data suggest that gamma-secretase inhibition attenuates
apoptosis induced by chemotherapeutic agents in colon cancer.

The Combined Use of Oxaliplatin and MRK-003 Increases Long-Term Survival in vitro
We hypothesized the attenuation of apoptosis seen in cells treated with
oxaliplatin and MRK-003 might be due to increased survival, as measured by MTT
assay and cell cycle analysis. HCT-116 and SW480 were treated for 48 hours with
oxaliplatin with or without MRK-003 and survival was measured by MTT assay. As
expected, oxaliplatin treatment decreased viability by approximately 60% for both cell
lines; the combination of oxaliplatin and MRK-003 showed no difference compared to
oxaliplatin alone (Figure 12a). MRK-003 alone had no effect on viability compared to
vehicle in either cell line.
Cell cycle analysis showed oxaliplatin induced a G2-M arrest in HCT-116 that
remained unchanged with the addition of MRK-003; the percentage of cells in G0/G1,
however, increased (21% to 32%, respectively) (Figure 12b). Oxaliplatin arrested
SW480 cells in S phase and no change was observed with the addition of MRK-003 in
the cell cycle profile (Figure 12b). MRK-003 alone increased the G0/G1 fraction from
34% to 48% in HCT-116.

33

Figure 12: Oxaliplatin and MRK-003 Does Not Affect Short-Term Survival
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) Oxa
for 48 hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK003. After treatment, MTT for viability (A) or cell cycle analysis (B) was performed.
Represented data are mean +/- SEM of three independent experiments.
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Colony forming assays are a measure of long-term survival. Cell death may be
mediated through non-apoptotic mechanisms or may be delayed. The combination of
oxaliplatin and MRK-003 remarkably enhanced colony formation in both HCT-116 and
SW480 when compared to oxaliplatin-treated alone (Figure 13). Collectively, the data
suggests that GSI enhances the survival of cells treated with oxaliplatin.

Figure 13: Oxaliplatin and MRK-003 Does Not Affect Short-Term Survival
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) Oxa
for 48 hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK003. After treatment, MTT for viability (A) or cell cycle analysis (B) was performed.
Represented data are mean +/- SEM of three independent experiments.

Attenuation of the Apoptotic Signaling Cascade
The mechanisms underlying gamma-secretase inhibition on oxaliplatin-induced
apoptosis was examined by evaluating changes in the classical apoptotic signaling
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cascade. Cells treated with oxaliplatin and MRK-003 blocked cleavage of PARP (Figure
14) and caspase-3 (Figure 8) in both HCT116 and SW480 as measured by western blot
and flow cytometry, respectively. Caspase activity can be blocked through direct
interaction with the inhibitor of apoptosis protein (IAP) family members c-IAP1, c-IAP2
and XIAP, but no differences in protein levels were detected by western blot (data not
shown). Second, oxaliplatin-induced cytochrome c release in both HCT-116 and
SW480 was blocked by the addition of MRK-003 (Figure 15).

Figure 14: The Combination of Oxaliplatin and MRK-003 Reduces PARP Cleavage
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) for 48
hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-003.
Full-length (110 kDa) and cleaved (80 kDa) PARP was analyzed by western blotting of
whole cell lysates. Equal protein loading was shown by probing for beta-actin.
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Figure 15: The Combination of Oxaliplatin and MRK-003 Reduces Cytochrome c
Release
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) for 48
hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-003.
Release of cytochrome c into cytosolic fraction was analyzed by western blot. Potential
mitochondrial contamination was detected by COX-IV (positive control lane is a whole
cell extract). Beta-actin was used as a loading control.

Bax and Bak are the two key pro-apoptotic proteins that regulate cytochrome c
release. Bax and Bak are activated by conformational changes to promote homooligomerization to create pore-like channels responsible for cytochrome c release
(reviewed in (Tait et al. 2010)). The activation of Bax and Bak can be assessed using
conformation specific antibodies (6A7 for Bax and Ab-1 for Bak) (Hsu et al. 1998). To
determine if MRK-003 altered the activation of Bax and Bak in oxaliplatin-treated cells,
Bax and Bak were immunoprecipitated with their active conformation specific antibodies
and western blotted. In response to oxaliplatin, both HCT-116 and SW480 show
activation of Bax and Bak, which was markedly inhibited in the presence of MRK-003
(Figure 16).
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Figure 16: The Combination of Oxaliplatin and MRK-003 Reduces Bax and Bak
Activation
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) for 48
hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-003.
Immunoprecipitation of active Bax and Bak. Whole cell extracts were probed for total
Bax, total Bak, and beta-actin.

Mcl-1 and Bcl-xL levels are Elevated in Oxaliplatin + GSI treated Cells
The activation of Bax and Bak can be prevented by the anti-apoptotic Bcl-2
family member proteins Bcl-2, Bcl-xL, Mcl-1, Bcl-w, and A1 (Brunelle et al. 2009).
Gamma-secretase inhibition has been shown to regulate protein expression of the Bcl-2
family members (Wang et al. 2010; Ramakrishnan et al. 2012). We tested whether or
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not GSI treatment altered total protein levels of Mcl-1 or Bcl-xL (neither cell line
expressed detectable levels of Bcl-2, data not shown). Cells treated with MRK-003
alone increased Mcl-1 protein levels without seemingly affecting Bcl-xL levels in both
HCT-116 and SW480 (Figure 17). The combination of oxaliplatin and MRK-003 lead to
enhanced protein levels of both Mcl-1 and Bcl-xL as compared to oxaliplatin alone in
both cell lines.

Figure 17: MRK-003 Increases Protein Expression of Mcl-1 and Bcl-xL
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) for 48
hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-003.
Total levels of Mcl-1 and Bcl-xL were assessed by immunoblotting. Beta-actin was
used as a protein loading control.
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Figure 18: Knockdown of Mcl-1 and/or Bcl-xL Rescues MRK-003 Attenuation of
Oxaliplatin-induced Apoptosis
(A) HCT-116 was transfected with increasing amounts of Mcl-1 siRNA as indicated for
24 hours. Cells were then treated with 15 µM Oxa in the absence or presence of 10 µM
MRK-003 for 48 hours. Apoptosis rates were measure by flow cytometry following
active caspase-3 reactivity. Represented data are mean +/- SEM of two independent
experiments. (B) Western blot shows efficiency of Mcl-1 knockdown.

Knockdown or Pharmacologic Inhibition of Mcl-1 and/or Bcl-xL Restores Apoptosis in
Cells Treated with Oxaliplatin and MRK-003
To examine whether the MRK-003 induced increase in the anti-apoptotic proteins
Mcl-1 and/or Bcl-xL is responsible for decreased sensitivity to oxaliplatin treatment, we
used RNAi interference (siRNA) assays to silence Mcl-1 and/or Bcl-xL.
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Figure 19: Knockdown of Bcl-xL Rescues MRK-003 Attenuation of Oxaliplatininduced Apoptosis
(A) HCT-116 was transfected with increasing amounts of Bcl-xL siRNA as indicated for
24 hours. Cells were then treated with 15 µM Oxa in the absence or presence of 10 µM
MRK-003 for 48 hours. Apoptosis rates were measure by flow cytometry following
active caspase-3 reactivity. Represented data are mean +/- SEM of two independent
experiments. (B) Western blot shows efficiency of Bcl-xL knockdown.

A dose-dependent knockdown of Mcl-1 resulted in a dose-dependent increase in
apoptosis in HCT-116 cells treated with oxaliplatin and MRK-003 but had no effect with
MRK-003 alone as measured by flow cytometry for active caspase-3 (Figure 18a).
Reduction of Bcl-xL levels in HCT-116 produced a similar dose-dependent increase in
apoptosis in cells treated with both oxaliplatin and MRK-003 (Figure 19Figure 18a).
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Figure 20: Simultaneous Knockdown of Mcl-1 and Bcl-xL Rescues MRK-003
Attenuation of Oxaliplatin-induced Apoptosis
(A) HCT-116 was transfected with 250 pM Mcl-1 and 25 pM Bcl-xL siRNA as indicated
for 24 hours. Cells were then treated with 15 µM Oxa in the absence or presence of 10
µM MRK-003 for 48 hours. Apoptosis rates were measure by flow cytometry following
active caspase-3 reactivity. Represented data are mean +/- SEM of two independent
experiments. (B) Western blot shows efficiency of Mcl-1 and Bcl-xL knockdown.

As expected, reducing levels of Mcl-1 or Bcl-xL lead to increased sensitivity to
oxaliplatin. Knockdown of Mcl-1 and Bcl-xL levels were confirmed by western blot
(Figure 18b, Figure 19b). Reducing the levels of both Bcl-xL and Mcl-1 with low
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picomolar doses greatly increased oxaliplatin-induced apoptosis, which was not
inhibited with the addition of MRK-003 (Figure 20a). Simultaneous knockdown of Mcl-1
and Bcl-xL levels were confirmed by western blot (Figure 20b)

Figure 21: Obatoclax Rescues MRK-003 Attenuation of Oxaliplatin-Induced
Apoptosis.
HCT-116 was treated with 15 µM Oxa in the absence or presence of 10 µM MRK-003
and/or 75 nM obatoclax (Obx) for 48 hours. SW480 was treated with 30 µM Oxa in the
absence or presence of 5 µM MRK-003 and/or 25 nM obatoclax for 48 hours.
Apoptosis rates were measured by flow cytometry following active caspase-3 reactivity.
Represented data are mean +/- SEM of at least two independent experiments.

To further confirm the role of Mcl-1 and Bcl-xL in mediating the abrogation of oxaliplatininduced apoptosis by MRK-003, we used the BH3-peptide mimetic obatoclax (GX15070) to broadly antagonize Bcl-2 pro-survival family members Mcl-1 and Bcl-xL.
Apoptosis inhibition associated with the combination of oxaliplatin and MRK-003
treatment was reversed with the addition of obatoclax in both HCT-116 and SW480
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(Figure 21). Of note, the combination of MRK-003 and obatoclax also resulted in an
increase in apoptosis in HCT-116 (Figure 21). Thus, inhibiting Mcl-1 and/or Bcl-xL
through RNA interference or small molecule inhibitor (obatoclax) lead to a restoration of
apoptosis in colon cancer.

Discussion
In this study, we report that the combination of the gamma-secretase inhibitor
MRK-003 with oxaliplatin elicited potent chemoresistance in colon cancer cells by
greatly decreasing apoptosis and leading to increased long-term survival. We showed
the combination of oxaliplatin and MRK-003 reduced apoptosis in HCT-116, SW480,
HCT-15, HT-29, and Colo205 colon cancer cell lines by at least half. The reduction in
apoptosis could be replicated using alternative GSIs (DAPT and GSI-XX) in HCT-116
and SW480. GSI-XII, a fourth GSI used in this study, slightly increased apoptosis by
10% in HCT-116 and only decreased apoptosis by approximately 7% in SW480. None
of the four GSIs used in this study elicited apoptosis by themselves. When MRK-003
was combined with other chemotherapeutic agents (etoposide and irinotecan),
decreased apoptosis was also seen in HCT-116. MRK-003, however, had no effect on
apoptosis of etoposide- or irinotecan-treated SW480 cells, a finding reported elsewhere
using DAPT in combination with various chemotherapeutic agents (Akiyoshi et al.
2008). These data suggest that the effects seen are not cell-context specific, mediated
by gamma-secretase inhibition (not an off-target effect), and not unique to oxaliplatin
treatment. We observed no change in viability in oxaliplatin-treated cells with or without
MRK-003 in either HCT-116 or SW480. Cell cycle analysis showed a slight increase in
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G0/G1 arrest with the addition of MRK-003 in oxaliplatin-treated HCT-116 cells alone (no
change was observed in SW480). These data do not account for the reduction in
apoptosis seen with MRK-003 treatment. However, to further support the decrease in
apoptosis observed in oxaliplatin and MRK-003 treated cell, long-term survival assays
showed increased cell survival in combination treatment compared to oxaliplatin alone.
We identified increased protein levels of the anti-apoptotic Bcl-2 family members
Mcl-1 and Bcl-xL in response to MRK-003 as pivotal players responsible for decreased
oxaliplatin-induced apoptosis, leading to a reduction of Bax and Bak activation and
downstream suppression of the apoptotic cascade (cytochrome c release, caspase-3
cleavage, and PARP cleavage). Restoration of apoptosis was achieved by blocking
Mcl-1 and/or Bcl-xL through RNA interference or the Mcl-1/Bcl-xL/Bcl-2 antagonist
obatoclax. Knockdown of Mcl-1 and/or Bcl-xL, however, did not induce apoptosis upon
GSI treatment alone but the combination of GSI and obatoclax did in HCT-116. From
these data, we conclude that increased protein levels of Mcl-1 and/or Bcl-xL are
responsible for the attenuation of oxaliplatin-induced apoptosis observed upon MRK003 treatment.
Several studies have highlighted the role of Notch signaling in the regulation of
Mcl-1 and Bcl-xL. Mcl-1 levels are decreased by blocking the Notch pathway via a GSI
(Wang et al. 2010) or with small-interfering RNA (Zhao et al. 2010) and increased by
overexpression of NICD (Wang et al. 2010). GSIs have been shown to increase Noxa,
a pro-survival BH3-only protein that promotes Mcl-1 degradation (Nefedova et al. 2008;
Seveno et al. 2012). Likewise, blocking Notch signaling can decrease Bcl-xL levels
(Nefedova et al. 2008; Vo et al. 2011). In contrast, our data shows increased protein
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levels of Mcl-1 and Bcl-xL upon GSI treatment. This phenomena has been replicated
by Liu et. al in T-ALL cell lines when examining the effect of gamma-secretase inhibition
on chemosensitivity. One subset of cells exhibited enhancement of apoptosis while
another subset showed resistance via upregulation of Bcl-xL (Liu et al. 2009). The
mechanism by which this occurs is still not well defined.
Our data also conflicts with other reports in the literature showing synergism
between cytotoxic agents and GSIs in colon cancer cell lines. One study showed that
blocking Notch-1 signaling using GSI34 (a novel gamma-secretase inhibitor) lead to an
enhancement of oxaliplatin sensitivity (Meng et al. 2009). Alternatively, DAPT
sensitized colon cancer cell lines SW480 and DLD-1 to paclitaxel only but not 5-FU,
camptothecin, TRAIL, or cisplatin (Akiyoshi et al. 2008). A third group tested the effects
of GSI-XX (DBZ), another GSI, in combination with platinum compounds (cisplatin,
carboplatin, and oxaliplatin) on a panel of 20 human colon cancer cell lines (Aleksic et
al. 2008). GSI-XX alone had no effect on cell survival and, in combination with cisplatin,
only a subset exhibited some degree of increased cell death; a few cell lines sensitive to
the combination of cisplatin and GSI-XX showed no effect with oxaliplatin or carboplatin.
In our hands, gamma-secretase inhibition using MRK-003, DAPT, or GSI-XX abrogated
oxaliplatin-induced apoptosis via increased Mcl-1 and/or Bcl-xL protein levels, as seen
by Liu et al. (Liu et al. 2009). The pleotropic nature of gamma-secretase inhibition on
chemotherapy-induced apoptosis is not well understood. It likely could be a reflection of
complex context-dependent signaling downstream of the Notch pathway, and thus may
only be of clinical utility to a particular (as yet undefined) subtype of colorectal cancer.
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The observed effects of MRK-003, DAPT, and GSI-XX on attenuating
chemotherapy-induced apoptosis may not be caused by Notch inhibition but rather
differential targeting of other known gamma-secretase substrates. Gamma-secretase
primarily catalyzes the intramembranous cleavage of Notch and APP (amyloid
precursor protein). However, it has also been shown to target at least a dozen known
type I transmembrane proteins, including E-cadherin, ErbB4, CD44, and c-Met, but their
mechanism and function is not well studied (for review, see (Haapasalo et al. 2011)).
Also, the specificity of GSIs for different substrates may drive the discrepancies found in
the literature, thus it will be important to understand the biochemical differences
between specific GSIs, particularly since we showed that GSI-XII did not have the same
effect as the other three GSIs. While we used four commercially available inhibitors
known to block both Notch cleavage and activity as well as induce apoptosis in multiple
tumor cell lines, we cannot rule out the possibility that these GSIs may also indirectly
target other molecular pathways, such as pro-apoptotic signaling pathways, which may
outweigh or antagonize any pro-apoptotic effects conferred by reduced Notch signaling
in colon cancer cells. Therefore, the contribution of single, combinatorial, or complete
ablation of all four Notch receptors on chemosensitivity is needed to address these
concerns. The newly emerging neutralizing antibodies to individual Notch receptors will
surely help to answer this question.
Standard chemotherapy approaches may need to be modified to include other
novel inhibitors. Despite the apparent discrepancies of gamma-secretase inhibition on
chemosensitivity, we were able to restore the attenuation of oxaliplatin-induced
apoptosis seen with MRK-003 by antagonizing Mcl-1 and/or Bcl-xL. Combining GSIs
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and chemotherapy with an anti-apoptotic Bcl-2 family member agonist like obatoclax
may be a valid therapeutic approach. We also found enhanced apoptosis with MRK003 and obatoclax combined. Previous studies have shown sensitization with the
combination of GSIs and the BH3 mimetic ABT-737 (antagonizes Bcl-2/Bcl-xL/Bcl-w but
not Mcl-1 (Oltersdorf et al. 2005)) in GSI-sensitive cell lines where GSI alone increased
Noxa levels, leading to subsequent Mcl-1 degradation (Li et al. 2010; Seveno et al.
2012). Our data shows MRK-003 synergism with obatoclax in GSI-resistant colon
cancer cell lines where GSI alone increases Mcl-1 and Bcl-xL levels. Therefore,
combining GSIs with other targeted therapeutics instead of chemotherapy may be a
more effective strategy in the treatment of colorectal cancer.
To our knowledge, the only published Phase II clinical trial studying the efficacy
of gamma-secretase inhibitor – RO4929097 – monotherapy in metastatic colorectal
cancer patients demonstrated no antitumor effects (Strosberg et al. 2012).
Nevertheless, there are multiple clinical trials investigating mono- and combination
therapies involving GSIs in a wide variety of tumors (www.clinicaltrials.gov). The results
posed here do not diminish the potential use of GSIs in a clinical setting but rather
suggest caution when developing drug combinations. First, further detailed mechanistic
studies looking at the biochemical differences in substrate specificity and potential offtarget effects of the many available GSIs are needed. Also, the effects of gammasecretase inhibition in relation to cell context and interactions with signaling pathways
needs further clarification as there are clear indications that GSIs can have opposing
effects even in same tumor types. Third, the potential still exists for using GSIs in
combination with other therapeutic agents to elicit anti-tumorigenic responses. Our
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results provide a cautionary tale for broad application of gamma-secretase inhibitors.
Understanding the actions of this drug when used in combination with standard
chemotherapy and/or targeted therapies will provide greater knowledge of its potential
use for a personalized approach to cancer treatment.
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CHAPTER FOUR: TARGETING AUTOPHAGY-SENSITIZED COLON CANCER
CELLS TO GAMMA-SECRETASE INHIBITORS

Abstract
Gamma-secretase has been considered an attractive target for colorectal cancer
due to its ability to block Notch signaling. In the previous section, we found that
gamma-secretase inhibitors (GSIs) alone had no effect on cell proliferation or apoptosis
in human colorectal cancer cell lines. When GSIs were combined with chemotherapy,
apoptosis was abrogated and long-term survival increased. The combination of
oxaliplatin, the first line of chemotherapy for colorectal cancers, with MRK-003, a
specific GSI, resulted in elevated levels of anti-apoptotic Bcl-2 family members Mcl-1
and Bcl-xL. Addition of the Bcl-2 inhibitor obatoclax (Obx) and knockdown of Mcl-1
and/or Bcl-xL were able to, at least partially, restore apoptosis. Interestingly, the
combination of MRK-003 and obatoclax induced cell death.
We show here that cell death due to the combination of MRK-003 and obatoclax
was only partially due to apoptosis in HCT-116 and SW480 by measuring Annexin-V
positivity, Parp-1 cleavage, caspase-3 cleavage, and effects on death using the pancaspase inhibitor z-VAD-fmk. Obatoclax has been shown to induce autophagy, a
cannibalistic cell survival pathway activated upon cellular stress. We examined if
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autophagy played a role in increasing cell death due to the MRK-003 + Obx
combination.
We measured autophagic flux, the complete process of autophagy initiation and
progression leading to the release of degraded substrates, by the bafilomycin A1 clamp
assay and total p62 levels. The bafilomycin A1 clamp assay prevents LC3-II
degradation, a protein that is generated during autophagic flux initiation and degraded
upon completion; p62 is a degraded during autophagic flux. Our data indicates that
autophagy is blocked with the combination of MRK-003 and obatoclax. We saw no or
little decrease in LC3-II levels with the bafilomycin clamp assay and increased total p62
levels. Our data also indicated that each drug alone induced autophagy. What remains
unclear is how blockage of autophagy is attained with two drugs that individually induce
autophagy.
We are the first to show that gamma-secretase inhibitors stimulate cytoprotective
autophagy; this may be a reason for their insensitivity in our human colon cancer cell
lines. To address whether modulation of autophagy can sensitize GSI-treated colon
cancer cells, we blocked autophagy by the autophagy inhibitors 3-MA and bafilomycin
A1 and by knockdown of the critical autophagy genes Beclin-1 or Atg5. Blocking
autophagy with bafilomycin A1 and knockdown with both Beclin-1 and Atg5 increased
cell death in GSI-treated cells. The mechanism that stimulates autophagy is GSItreated cells remains unknown.
These findings suggest that one possible explanation for the insensitivity of colon
cancer cell lines to GSI treatment is the induction of cytoprotective autophagy. This
calls into question the validity of using GSIs to treat colon cancer patients
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Results
Apoptosis is Partially Responsible for Cell Death Induced by the Combination of MRK003 and Obatoclax
In the previous chapter, we observed high levels of cell death under the
microscope in HCT-116 and SW480 cells when treated with both MRK-003 and
obatoclax compared to either drug alone. However, only 12% and 4% of HCT-116 or
SW480 cells, respectively, were positive for active caspase-3 (Figure 8b). To further
characterize the role of apoptosis in the observable cell death, HCT-116 and SW480
were treated with both drugs and apoptosis was assessed 48- hours post treatment by
Annexin-V & 7-AAD staining. HCT-116 cells showed similar levels of early apoptosis
[Annexin-V (+) / 7-AAD (-)] and late apoptotic / dead [Annexin-V (+) / 7-AAD (+)] cells in
MRK-003 + Obx treated cells (Figure 22a). SW480, however, had almost no early
apoptotic positive cells; most labeled positive for late apoptosis / dead (Figure 22b).
Similarly, higher Parp-1 cleavage, a marker of apoptosis, was observed in HCT-116 by
western blot in MRK-003 + Obx treated cells as early as 24 hours but no detectable
levels of Parp-1 cleavage was observed in SW480 by 48 hours (Figure 25a-b). Cell
death also assessed using the vital dye propidium iodide (PI), which is excluded from
live cells, resulted in similar levels of cell death when compared to the Annexin-V & 7AAD assay in both HCT-116 and SW480 (Figure 23). Cell death will henceforth be
assessed by PI staining for all following experiments.

52

Figure 22: Contribution of Apoptosis in Cell Death Mediated by the Combination
of MRK-003 and Obatoclax
HCT-116 (A) and SW480 (B) cells were treated with 10 µM (HCT-116) or 5µM (SW480)
MRK-003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480)
obatoclax (Obx) for 48 hrs. Apoptosis rates were measure by flow cytometry following
Annexin-V/7-AAD staining. Represented data are mean +/- SD of two independent
experiments.
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Figure 23: The Combination of MRK-003 and Obatoclax Induces Cell Death in
Human Colon Cancer Cell Lines
HCT-116 (A) and SW480 (B) cells were treated with 10 µM (HCT-116) or 5µM (SW480)
MRK-003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480)
obatoclax (Obx) for 48 hrs. Cell death rates were measure by flow cytometry following
PI staining. Represented data are mean +/- SD of two independent experiments.

The classical markers of apoptosis, viable Annexin-V positivity, caspase-3
cleavage, and Parp-1 cleavage, were present in HCT-116 but not SW480. To
determine if apoptosis is the only mechanism responsible for the observed cell death,
HCT-116 and SW480 were treated with MRK-003 and Obx in the presence or absence
of the pan caspase inhibitor z-VAD-fmk. Oxaliplatin-treated cells were used as a
positive control to show greater than 50% suppression of cell death in the presence of
z-VAD-fmk. The addition of z-VAD-fmk to MRK-003 + Obx-treated cells suppressed cell
death by 50% in HCT-116 and 20% in SW480 (Figure 24). Interestingly, z-VAD-fmk
had no effect on cell death on Obx-treated cells in HCT-116. These data suggest an
alternative cell death mechanism may be responsible for killing even when apoptosis is
inhibited.
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Figure 24: MRK-003 + Obx-induced Cell Death is Partially Inhibited by Z-VAD-FMK
HCT-116 (A) was treated with 10 µM MRK-003 (GSI) and 75 nM obatoclax (Obx) in the
presence or absence of 20 µM z-VAD-fmk for 48 hrs. SW480 (B) was treated with 5 µM
MRK-003 and 75 nM Obx in the presence or absence of 20 µM z-VAD-fmk for 48 hrs.
Cells were treated with 50 µM oxaliplatin (Oxa) as a positive control. Cell death rates
were measure by flow cytometry following PI staining. Represented data are mean +/SD of two independent experiments.
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Figure 25: Total Levels of LC3-II are Increased in MRK-003 + Obx Treated Cells
HCT-116 (A) and SW480 (B) cells were treated with 10 µM (HCT-116) or 5µM (SW480)
MRK-003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480)
obatoclax (Obx) for 48 hrs. Total levels of LC3-II and PARP-1 were assessed by
western blot. Beta-actin was used as a protein loading control.

Cytoprotective Autophagy is Blocked in MRK-003 + Obatoclax-Treated Cells
In addition to repressing apoptosis, the anti-apoptotic Bcl-2 family proteins can
also directly bind to Beclin-1, preventing autophagy initiation (Rahmani et al. 2012; Tang
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et al. 2012; Schwartz-Roberts et al. 2013). Autophagy, a process of recycling cellular
material for energy, is thought to act as a survival process during times of stress.
Therefore, obatoclax may both promote apoptosis and facilitate autophagy
simultaneously. Measuring autophagy must be performed using multiple assays as no
single assay provides conclusive information.
Total LC3-II protein levels, a specific autophagic marker, was assessed in HCT116 and SW480 cells treated with MRK-003 or obatoclax, alone or in combination, by
western blot. First, we found slight increases in LC3-II levels in both cell lines with each
drug alone compared to untreated controls; levels were further elevated in combination
treatment (Figure 25).

Figure 26: Increased Acidic Vesicular Organelles by Acridine Orange Staining in
MRK-003 + Obx Treated Cells
HCT-116 and SW480 cells were treated with 10 µM (HCT-116) or 5µM (SW480) MRK003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480) obatoclax
(Obx) for 48 hrs. Autophagic vesicles were detected in live cells by acridine orange
staining and examined by fluorescence microscopy.
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When autophagosomes fuse with the acidic lysosomes, the resultant
autolysosome is an acidic compartment. Acridine Orange (AO) is a dye used to detect
autophagic vesicles. Acridine orange is an acidotropic (pH sensitive) dye that crosses
into lysosomes (and other acidic compartments) within the cell where it becomes
protonated and trapped within the organelle and then forms aggregates that emit red
fluorescence; at neutral pH, the unprotonated dye emits green fluorescence. Detection
of acidic vesicular organelles (AVOs), a morphologic characteristic of autophagy, by
acridine orange staining was qualitatively analyzed using an inverted fluorescent
microscope. The combination of MRK-003 and obatoclax showed increased staining of
AVOs as compared to control or either drug alone in HCT-116; no differences could be
seen in SW480 (Figure 26).

Figure 27: Elevated Levels of p62 in MRK-003 + Obx Treated Cells
HCT-116 (A) and SW480 (B) cells were treated with 10 µM (HCT-116) or 5µM (SW480)
MRK-003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480)
obatoclax (Obx) for 48 hrs. Total level of p62 was assessed by western blot. Beta-actin
was used as a protein loading control.
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The protein p62 is degraded during autophagy induction and serves as another
autophagy marker; p62 levels should inversely correlate with LC3-II levels during
autophagy promotion. When p62 was measured in treated cells, we found increased
protein levels in MRK-003 + Obx-treated cells compared to either drug alone (Figure
27). The increase in p62 levels do not inversely correlate with LC3-II levels, suggesting
that autophagy is not being promoted in combined treatment to elicit cell death.
To address this inconsistency, we must reevaluate what information total
LC3-II levels provide. Elevated LC3-II protein levels can indicate either: 1) increased
autophagy induction or 2) blockage in autophagy. LC3-II has a half-life of approximately
30 minutes. If autophagy is inhibited by blocking the fusion of the autophagosome to
the lysosome for a period of time, allowing for accumulation of LC3-II without
subsequent degradation, we can compare the levels of LC3-II in these cells to their
unblocked counterpoint to determine whether autophagy is being induced or blocked.
This feature can be exploited by the bafilomycin A1 clamp assay (Rubinsztein et al.
2009). In this assay, cells are treated with the compound of interest and during the last
four hours of treatment, saturating concentration of bafilomycin A1, a drug that blocks
the fusion of the autophagosome with the lysosome, is added. When comparing cells
treated with bafilomycin A1 to those without, increased levels of LC3-II would indicate
induction of autophagy while decreased or no change in LC3-II levels would indicate a
block in autophagy. When MRK-03 + Obx treated HCT-116 and SW480 cells were
subjected to the bafilomycin A1 clamp assay, we saw a decrease in LC3-II levels in the
presence of Baf A1 in HCT-116 (Figure 28a, compare lanes 8 to 4) and no change in
LC3-II levels in SW480 (Figure 28b, compare lanes 8 to 4).
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Figure 28: Blocked Autophagic Flux in MRK-003 + Obx Treatment and Increased
Autophagic Flux in GSI Treatment
HCT-116 (A) and SW480 (B) cells were treated with 10 µM (HCT-116) or 5µM (SW480)
MRK-003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480)
obatoclax (Obx) for 48 hrs. During the last four hours, cells were treated with 400 nM
bafilomycin A1 for 4 hours and harvested. Total level of LC3-II was assessed by
western blot. Beta-actin was used as a protein loading control.

We see an increase in LC3-II levels in the presence of Baf A1 for each drug alone in
both HCT-116 (Figure 28a, compare lanes 6 to 2 and lanes 7 to 3) and SW480 (Figure
28b, compare lanes 6 to 2 and lanes 7 to 3). These data indicate that both MRK-003
and obatoclax alone may promote autophagy but when combined, autophagy is
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somehow blocked. In summary, we see an absence (with MRK-003 alone) or lower
levels (with obatoclax alone) of cell death with simultaneous autophagy induction in our
colon cell lines; increased cell death (with MRK-003 + Obx combined treatment) is
observed simultaneously with blocked autophagy. Our findings suggest a
cytoprotective role for autophagy in this cellular context. It remains unclear how the
combination of MRK-003 and obatoclax blocks autophagy when both drugs alone
promote it.

Blocking Autophagy Sensitizes Colon Cancer Cells to GSI Treatment
If we instead focus on the data suggesting induction of cytoprotective autophagy
in insensitive GSI treated colon cancer cells, we can hypothesize that blocking
autophagy may overcome their resistance. To test this, we treated colon cells with two
common compounds used to suppress autophagy – 3-MA and bafilomycin A1 (note:
neither compound is a specific autophagy inhibitor). 3-MA is a nucleotide derivative that
blocks class III PI3 kinases and prevents autophagy initiation (Seglen et al. 1982).
When treated with 3-MA, we did not see sensitization of GSI-treated HCT-116 or
SW480 cells (Figure 29a-b). As expected, 3-MA did increased cell death in obatoclaxtreated cells and in GSI + Obx treated HCT-116. Bafilomycin A1, an ATPase inhibitor,
blocks fusion of the autophagosome to the lysosome. When treated with bafilomycin
A1, we saw massive increases in cell death in GSI-treated HCT-116 (Figure 30).
Bafilomycin A1 had no effect on cell death in Obx-treated or MRK-003 + Obx-treated
cells.
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Figure 29: Blocking Autophagy through 3-MA Does Not Sensitize GSI-treated
Cells
HCT-116 (A) was treated with 10 µM MRK-003 (GSI) and 75 nM obatoclax (Obx) in the
presence or absence of 5 mM 3-MA for 48 hrs. SW480 (B) was treated with 5 µM MRK003 and 75 nM Obx in the presence or absence of 5mM 3-MA for 48 hrs. Cell death
rates were measure by flow cytometry following PI staining. Represented data are
mean +/- SD of two independent experiments.
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Figure 30: Blocking Autophagy with Bafilomycin A1 Induces Cell Death in GSItreated Cells
HCT-116 was treated with 10 µM MRK-003 (GSI) and 75 nM obatoclax (Obx) in the
presence or absence of 10 nM bafilomycin A1 for 48 hrs. Cell death rates were
measure by flow cytometry following PI staining. Represented data are mean +/- SD of
two independent experiments.

To further characterize the cytoprotective role of autophagy mediating GSI
insensitivity, we knocked down two essential autophagy proteins – Beclin-1 and Atg5 –
by RNAi techniques. Beclin-1 is required during the vesicle nucleation step of
autophagy. Partial knockdown of Beclin-1 resulted in 40% cell death; treatment with
MRK-003 increased cell death to ~60% (Figure 31a). Atg5 is required to convert LC3-I
to LC3-II during autophagosome formation. Partial knockdown of Atg5 sensitized cells
to MRK-003, increasing cell death by ~15% (Figure 31a). Knockdown was verified by
western blot (Figure 31b). These data further support the theory that inhibition of
autophagy may sensitize colon cells to gamma-secretase inhibitors.
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Figure 31: Knockdown of Beclin-1 or Atg5 Increases Cell Death in GSI-treated
Cells
HCT-116 was transfected with 50 nM siRNA (Control, Beclin-1, or Atg5) for 24 hours
and then treated with 10 µM MRK-003 (GSI) and 75 nM obatoclax (Obx) 48 hrs. Cell
death rates were measure by flow cytometry following PI staining. Represented data
are mean +/- SD of two independent experiments.

Discussion
Here, we show that the GSI MRK-003 in combination with obatoclax induces cell
death in colon cancer cell lines. Others have shown increased killing with the
combination of GSI and anti-apoptotic Bcl-2 agonists but we are the first to report a role
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for autophagy in mediating cell death with combination treatment. Apoptosis seems to
only have a partial role in this cell death induction. HCT-116 exhibited features of
apoptosis by Annexin-V positivity and Parp-1 cleavage, both absent in SW480. Neither
cell line showed significant caspase-3 cleavage. Inhibition of apoptosis by z-VAD-fmk
blocked MRK-003 + Obx induced cell death by 50% in HCT-116 and 20% in SW480.
Therefore, we concluded that apoptosis was not sufficient in mediating cell death
induced by the combination of MRK-003 and obatoclax.
Obatoclax also induces autophagy, likely through antagonizing the anti-apoptotic
Bcl-2 family members Mcl-1 and Bcl-xL, which in addition to blocking apoptosis, can
also block autophagy via direct binding to Beclin-1 (see above). We decided to assess
the modulation of autophagy with this combination to examine its role in mediating the
cell death observed. Alone, MRK-003 and obatoclax both promote autophagic flux.
However, in combination, autophagy is inhibited. Our data showed no change or
decreased levels of LC3-II during the bafilomycin clamp assay and increased p62
protein levels, all indicators of blocked autophagic flux. The mechanism for this remains
unknown.
Only one report has looked at the effect of GSIs on modulation of autophagy in
mouse embryonic fibroblasts; they found no differences in autophagy (Neely et al.
2011). We show are the first to show that the GSI MRK-003 increases autophagic flux
in both HCT-116 and SW480. It remains unclear how this occurs as MRK-003 also
increases protein levels of Mcl-1 and to some extent Bcl-xL, which in theory should
block autophagy. Cytoplasmic localization of these proteins may explain this
inconsistency, as only ER-localized, not mitochondria-localized, anti-apoptotic Bcl-2
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protein can inhibit autophagy (Pattingre et al. 2005). Therefore, if Mcl-1 and/or Bcl-xL
are not translocated to the ER even with increased total protein levels, autophagy will
not be blocked. Induction of autophagy in GSI-treated cells may be due to a general
stress response or due to specific mechanism of action by GSI. This is an area that
needs to be further explored.
As mentioned, we are the first to show that cytoprotective autophagy may
contribute to GSI-insensitivity in human colon cancer cell lines. We targeted autophagy
via two chemical inhibitors – 3-MA and bafilomycin A1 – or through RNAi to examine its
role in mediating GSI sensitivity. We found that bafilomycin A1, but not 3-MA,
dramatically induced cell death in GSI-treated cells. Why both compounds did not have
similar effects is unknown but this phenomenon has been reported in the literature
(Shingu et al. 2009; Kanematsu et al. 2010). To address this, other autophagy inhibiting
compounds, like chloroquine, need to be utilized. In addition to pharmacologically
inhibiting autophagy, we knocked down two critical autophagy proteins – Beclin-1 and
Atg5 – via RNAi. Knockdown of both Beclin-1 and Atg5 enhanced cell death in GSItreated cells by ~20%. Our data supports a cytoprotective role of autophagy in
sensitivity to GSIs in human colon cancer cell lines. Other GSI-insensitive cell types,
i.e. breast cancer cell lines, need to be examined to determine if autophagy induction by
GSI is universal. Therefore, we concluded that targeting autophagy in GSI-insensitive
human colon cancer cell lines might be a rational approach to render cells sensitive to
GSI treatment.
As mentioned previously, GSIs have yet to show any clinical significance in the
treatment of colorectal cancer. We are the first to show that GSI insensitivity is due to
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cytoprotective autophagy induction, though other mechanisms, like increased antiapoptotic Bcl-2 family proteins, may also play a role. Our data supports the theory of
targeting autophagy to modulate GSI sensitivity and therefore, combination of GSIs with
autophagy inhibitors may be clinically useful.
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CHAPTER 5: CONCLUSION

In conclusion, we show two potential drug resistance mechanisms to gammasecretase inhibitors when given in combination with chemotherapy or as a single agent
in colorectal cancer cells.
In the first scenario, combination of the GSI MRK-003 with oxaliplatin, the first
line of chemotherapy for colorectal cancer patients, resulted in attenuation of apoptosis
in the colon cancer cell lines HCT-116, SW480, HT-29, HCT-15, and Colo205.
Abrogation of chemotherapy-induced apoptosis by GSIs was further supported by using
alternative GSIs (DAPT and GSI-XX) and by other chemotherapeutic agents (etoposide
and irinotecan). Decreased apoptosis seen in the combination of oxaliplatin and MRK003 resulted in increased colony formation (long-term survival) compared to oxaliplatin
treatment alone, refuting the possibility of delayed apoptosis. A decrease in the entire
apoptotic cascade, from caspase-3 cleavage, cytochrome c release, and Bax and Bak
activation, was observed in the combination of oxaliplatin and MRK-003. We found an
increase in protein levels of the anti-apoptotic protein Mcl-1 with MRK-003 treatment
alone and in combination with oxaliplatin compared to control and oxaliplatin-treated
cells, respectively. We also observed elevated levels of the anti-apoptotic protein BclxL with the combination of oxaliplatin and MRK-003 compared to oxaliplatin treatment
alone. We knocked-down both proteins, individually and simultaneously, and
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pharmacologically inhibited them with their agonist obatoclax to show that Mcl-1 and/or
Bcl-xL played a causative role in the attenuation of oxaliplatin-induced apoptosis by the
GSI MRK-003.
In the second scenario, we have shown that the GSI MRK-003 has little to no
effect on cell death as a single agent in colon cancer cell lines. However, we did
observe high levels of cell death in the combination of MRK-003 and obatoclax that was
only partially (in HCT-116) or not (in SW480) due to apoptosis. Literature has
supported a role of the anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1 in preventing
autophagy through binding and sequestering the autophagy protein Beclin-1. As
autophagy is primarily a survival mechanism of the cell during times of stress, degrading
proteins and cellular material for recycling and energy production, we assessed the
modulation of autophagy in the combination of MRK-003 and obatoclax. Both MRK-003
and obatoclax promoted autophagic flux as single agents but inhibited autophagy in
combination. Why two agents that individually promote autophagy block it in
combination remains unknown. However, we were intrigued by the fact that the GSI
MRK-003 induced autophagy and hypothesized that blocking autophagy could sensitize
colon cells to GSIs. We blocked autophagy via two chemical inhibitors – 3-MA and
bafilomycin A1 – and through knockdown of the autophagy proteins Beclin1 and Atg5 to
show sensitization to MRK-003 in autophagy-deficient colon cancer cell lines.
The results of this work have important implications for the clinical use of GSIs.
While this work provides a cautionary tale for the use of GSIs alone or in combination
with chemotherapy in the treatment of colorectal cancer, the apoptosis inhibition or
autophagy induction seen may be off-target effects of GSIs and not due to
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downregulation of Notch signaling. Newly developed monoclonal Notch receptor
antibodies will need to be tested in vitro and in vivo to address this issue. Furthermore,
because Notch signaling can be both oncogenic and tumor suppressive, we need to
determine what tumor types will potentially benefit from GSIs. Multiple ongoing Phase I
and II clinical trials in both liquid and solid tumors are underway utilizing a variety of
GSIs (MRK-0752 Merck, RO4929097 Roche, BMS-906024 Bristol-Meyers Squibb, and
PF-03084014 Pfizer) as single agents or in combination with chemotherapy or other
targeted drugs to address this issue. One small Phase II clinical trial using RO4929097
in refractory metastatic colorectal patients showed no radiographic response; in vitro
experiments using GSIs in colon cancer cell lines have resulted in conflicting data
(Strosberg et al. 2012). It is clear likely that the indicated study dosage and schedule
are not optimal to achieve measureable responses. It may also be possible that only
certain subsets of a tumor type may respond to GSI therapy and therefore biomarkers
identifying these subtypes will be useful.
We may instead need to rethink how targeting Notch signaling using GSIs can be
of clinical utility. There are conflicting reports of the role of Notch signaling in
tumorigenesis; evidence exists supporting both oncogenic and tumor suppressive
functions within tumor types. On one hand, the Notch pathway has been shown to be
upregulated in colorectal tumors compared to normal (Reedijk et al. 2008); a different
group has shown upregulation of the Notch pathway in low-grade adenomas but not
adenocarcinomas (Fre et al. 2009). In pancreatic cancer, recent work has also shown
differential effects of Notch pathway inhibition on precursor lesions (pancreatic
intraepithelial neoplasia, PanIN) and pancreatic ductal adenocarcinomas (PDAC).
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Treatment of mice PanIN lesions with GSIs lead to decreased progression whereas
treatment of PDAC lesions with GSIs had no effect on progression. Further studies
have revealed opposite effects of individual Notch receptors on pancreatic cancer
progression in mice – embryonic deletion of Notch1 produces advanced stage PanIN
lesions while embryonic deletion of Notch2 inhibits PanIN progression (Avila et al.
2013). Therefore, Notch signaling, and each individual receptor, may have differential
roles in tumor initiation and progression.
Additionally, drugs targeting developmental pathways like Notch may not work
like cytotoxic agents to kill cells but rather function to modulate cell fate programs to
sensitize cells to cytotoxic or growth arrest signals. Or, their main target might be
cancer-initiating cells rather than bulk tumor cells. Significant evidence exists for the
role of Notch signaling in the maintenance of a variety of tumor-initiating cells in the
colon (Sikandar et al. 2010), brain (Fan et al. 2006), breast (Wong et al. 2012), and Tcell leukemia (Armstrong et al. 2009). Therefore, the main therapeutic target of GSIs
may be stem-like tumor-initiating cells. In a recent study using Her2/Neu positive breast
xenographs in mice, the effect of two GSIs (MRK-003 and LY411,575) alone and in
combination with Herceptin (trastuzumab) was studied (Pandya et al. 2011). Herceptin
treatment alone lead to complete tumor regression; neither GSI had an effect alone or in
combination with Herceptin on tumor size. However, approximately 50% of Herceptintreated mice showed tumor recurrence; few (using LY411,575) to no (using MRK-003)
mice treated with the combination of Herceptin and GSI showed tumor recurrence.
Thus, GSIs may be clinically significant in limiting recurrence more than tumor
shrinkage.
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In conclusion, a comprehensive understanding of the role of Notch signaling,
especially the contribution of individual Notch receptors, in tumor initiation, progression,
metastasis, and recurrence needs further clarification. This will help determine whether
or not GSIs, or more targeted Notch receptor agonists, will be a valid therapeutic
approach to combating specific tumor subtypes.
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Gamma-secretase inhibition attenuates oxaliplatin-induced
apoptosis through increased Mcl-1 and/or Bcl-xL in human colon
cancer cells
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Abstract The Notch signaling pathway plays a significant role in differentiation, proliferation, apoptosis, and
stem cell processes. It is essential for maintenance of the
normal colon crypt and has been implicated in colorectal
cancer oncogenesis. Downregulation of the Notch pathway
through gamma-secretase inhibitors (GSIs) has been shown
to induce apoptosis and enhance response to chemotherapy
in a variety of malignancies. In this study, we analyzed the
effect of MRK-003 (Merck), a potent inhibitor of gammasecretase, on oxaliplatin-induced apoptosis in colon cancer.
Unexpectedly, gamma-secretase inhibition reduced oxaliplatin-induced apoptosis while GSI treatment alone was
shown to have no effect on growth or apoptosis. We
determined that the underlying mechanism of action
involved an increase in protein levels of the anti-apoptotic
Bcl-2 family members Mcl-1 and/or Bcl-xL which resulted
in reduced Bax and Bak activation. Blocking of Mcl-1 and/
or Bcl-xL through siRNA or the small molecule inhibitor
obatoclax restored the apoptotic potential of cells treated
with both oxaliplatin and MRK-003. Moreover, obatoclax
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synergized with MRK-003 alone to induce apoptosis. Our
findings warrant caution when treating colon cancer with
the combination of GSIs and chemotherapy, whereas other
drug combinations, such as GSIs plus obatoclax, should be
explored.
Keywords Gamma-secretase inhibitor ! Oxaliplatin !
Mcl-1 ! Bcl-xL ! Colon
Background
Colorectal cancer accounts for almost 50,000 deaths each
year in the United States and remains the third leading cause
of cancer-related mortality [1]. While surgical resection
remains the gold standard of treatment for localized disease,
chemotherapy combinations with oxaliplatin, irinotecan,
5-fluorouracil, the VEGF inhibitor bevacizumab, and EGFR
inhibitors have led to significant improvements in survival at
all stages [2, 3]. However, most metastatic colorectal cancer
patients eventually develop drug resistance to current therapies so new strategies are needed for treatment and
improved survival of these patients.
The Notch pathway is an evolutionarily conserved pathway important in cell differentiation, proliferation, apoptosis, cell fate decisions, and stem cell renewal during
development and cancer. The Notch family consists of four
trans-membrane receptors (Notch1–4) that are activated
upon binding to their ligands (Jagged 1–2 and Delta-like 1, 3,
and 4) located on adjacent cells, triggering two proteolytic
processing events. The first cleavage by TACE/ADAM
metalloproteases releases the extracellular domain followed
by gamma-secretase mediated cleavage to release the Notch
intracellular domain (NICD) [4]. The activated form of
Notch, NICD, translocates to the nucleus and binds to the
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transcriptional repressor CSL (CBF-1/suppressor of hairless/
Lag-1) and recruits MAML-1 (mastermind-like-1) and p300/
CBP to induce transcription of Notch target genes such as the
Hes (hairy/enhancer of split) and Hey family members [5],
c-myc, p21, and cyclin D1 (reviewed in [6]).
Aberrant activation of Notch signaling has been implicated in a variety of solid tumors, including breast [7, 8],
melanoma [9], ovarian [10], and prostate [11, 12]. It was first
linked to T cell acute lymphoblastic leukemia (T-ALL),
where [50 % of tumors harbored activating mutations
within Notch1 [13, 14]. In contrast, reduced Notch signaling
has been implicated in HPV-positive cervical cancer [15],
neuroendocrine tumors [16], small cell lung cancer [17],
hepatocellular carcinoma [18], and skin squamous cell carcinoma [19]. Indeed, the use of gamma-secretase inhibitors
(GSIs) in clinical trials for Alzheimer’s Disease (the amyloid
precursor protein—APP—implicated in this disease is a
gamma-secretase target) showed an increase risk of skin
cancer development [20]; decreased gamma-secretase
activity is also associated with increased skin cancer occurrence in mice [21]. Therefore, the biological outcome/
function of Notch signaling as oncogenic or tumor-suppressive is highly cell context specific (reviewed in [22]).
Inhibition of gamma-secretase has shown antitumor
effects in a variety of cancers in vitro and is thus considered an attractive pharmacology target. Pre-clinical reports
using cancer cell lines, patient samples in vitro, and in vivo
mouse models on the activity of MRK-003, a potent and
selective GSI, have reported Notch pathway inhibition and
antitumor activity in multiple myeloma [23], Non-Hodgkin’s leukemia [23], T-cell acute lymphoblastic leukemia
[24], breast cancer [25], pancreatic cancer [26, 27], lung
cancer [28], and glioblastoma [29].
Notch signaling plays a vital role in intestinal homeostasis, self-renewal, and cell fate decisions during postdevelopment [30–34] and is activated in colorectal adenocarcinomas [35, 36]. In theory, blocking Notch activation using GSIs might enhance chemotherapy effects for
the treatment of colon cancer. Here, we tested the capacity
for GSIs to synergize with oxaliplatin in colon cancer cell
lines and evaluated the underlying molecular mechanisms.
Surprisingly we show that GSIs blocked oxaliplatininduced apoptosis through increased protein levels of Mcl1 and/or Bcl-xL. Restoration of apoptosis was achieved by
blocking Mcl-1 and/or Bcl-xL with obatoclax or siRNA.

Materials and methods
Cell lines and chemicals
The human colorectal cancer cell lines HCT-116, HCT-15,
HT-29, and Colo205 were obtained from NCI; SW480 was

obtained from ATCC. All cell lines were grown in RPMI
1640 supplemented with 10 % FBS and L-glutamine and
grown in a 37 !C humidified camber 5 % CO2. Cells were
maintained for no more than 30 passages after thawing and
tested as mycoplasma-free. HCT-116 and SW480 cell lines
were authenticated using short tandem repeat (STR) DNA
typing according to ATCC’s ‘‘Authentication of Human
Cell Lines: Standardization of STR Profiling’’ (2012).
Oxaliplatin (Sigma) was suspended in 5 % dextrose.
The GSIs MRK-003 (a generous gift from Merck Inc),
DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)-S-phenylglycine]-t-butyl ester; Santa Cruz), GSI-XII (Calbiochem), and GSI-XX (DBZ; Calbiochem) and the Bcl-2
inhibitor obatoclax (GX15-070; Selleck) were suspended
in DMSO.

Apoptosis assays via flow cytometry
Apoptosis was measured by flow cytometry by detecting
activated Caspase-3 or by detecting Annexin-V. Cleaved
Caspase-3 was measured using the active caspase 3-FITC
Apoptosis Assay Kit (BD# 550480) according to the
manufacturer’s protocol. Data were acquired on a FACS
Scan or Calibur and analyzed with FlowJo software.
Apoptosis was also measured by AnnexinV-FITC (or
AnnexinV-APC) (BD# 556420 or 550475) and 7-AAD
staining according to the manufacturer’s protocol. Data
were acquired on a FACS Scan or Calibur and analyzed
with FlowJo software. Dot plots with the percentages of
each quadrant were reported for each sample.

Western blotting
Cell pellets were lysed in standard RIPA buffer (50 mM Tris
pH 7.4, 150 mM NaCl, 1 % Igepal CA-630, 0.5 % sodium
deoxycholate, and 0.1 % SDS) containing protease and
phosphatase inhibitors—1 lg/ml each of aprotin, leupeptin,
and pepstatin and 1 mM each of sodium fluoride, sodium
vanadate, phenylmethylsulfonyl fluoride, and sodium pyrophosphate—for 30 min on ice. Cell extracts were clarified by
centrifugation at 15,0009g for 10 min at 4 !C. Protein
concentration was determined via the Bradford Assay and
lysates were mixed 1:1 in 29 Laemmeli Sample Buffer and
heated at 95 !C for 5 min. 30 lg of protein was resolved onto
SDS-PAGE gels and transferred onto PVDF membranes.
Membranes were blocked in 19 TBST (Tris buffered saline
with 0.05 % Tween-20) supplemented with 5 % milk and
primary antibodies were incubated overnight at 4 !C in 1 %
BSA or 5 % milk dissolved in TBST. The primary antibodies
used for western blot were: rabbit anti-Mcl-1 (#5453), rabbit
anti-Bcl-xL (#2764), and rabbit anti-PARP (#9542) from
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Cell Signaling; mouse anti-b-actin (#A5441) from Sigma.
Membranes were washed and incubated with peroxidaseconjugated anti-mouse or anti-rabbit IgG secondary
antibodies (Jackson ImmunoReasearch Laboratories).
The signals were visualized using SuperSignal West
Pico Chemiluminescent detection reagent (Pierce/
ThermoScientific).

Cell cycle analysis

Cytochrome C release

Activation of Bax and Bak

Adherent and non-adherent cells were harvested by
scrapping and pelleted by centrifugation. For preparation of
cytosolic extracts, the cell pellet was immediately suspended in a cytochrome c permeabilization buffer (20 mM
Hepes pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, 250 mM Sucrose) containing
200 lg/ml Digitonin (Sigma# D141) supplemented with
protease and phosphatase inhibitors (see above in Western
blotting) and incubated on ice for 5 min. Lysates were
clarified by centrifugation at 1,0009g for 5 min at 4 !C to
remove unlysed cells, cell debris and nuclei. The supernatant transferred to a new tube and centrifuged at
20,0009g for 20 min at 4 !C to remove mitochondria and
any remaining debris. The supernatant was transferred to a
new tube and 20–30 lg of protein was subjected to western
blot analysis using anti-cytochrome c (BD# 556433) antibody. An anti-COX IV (Cell Signaling# 4580) antibody
was used as a control to measure mitochondrial contamination of cytosolic extracts.

Cell pellets were lysed in CHAPS lysis buffer (1 %
CHAPS, 150 mM NaCl, 1 mM Hepes pH 7.4) containing
protease and phosphatase inhibitors (see above for details)
for 1 h on ice. Lysates were centrifuged and protein concentration was determined by Bradford assay. 500 lg of
protein was precleared with 20 ll of anti-mouse IgG
(whole molecule)-agarose beads (Sigma# A6531) for 1 h at
4 !C with rotation. The beads were pelleted and the
supernatant was transferred to a new tube. Activated Bax or
Bak was immunoprecipitated with 2 lg of anti-Bax 6A7
(Sigma# B8429) or anti-Bak Ab-1 (Calbiochem# AM03)
antibodies and 20 ll of anti-mouse IgG-agarose beads and
incubated overnight at 4 !C with rotation. The beads were
pelleted and washed three times in CHAPS lysis buffer
before being subjected western blot analysis with rabbit
anti-Bax (N-20, #sc-493) and rabbit anti-Bak (G-23, #sc832), respectively (Santa Cruz).

Cell survival and colony formation assays
Short-term cell survival was measured by MTT assay.
Cells were seeded into 96-well plates in quadruplicate
and drug treated the next day for 48 h. MTT
((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma# M2128) was added at a final concentration
of 0.5 lg/uL per well and incubated for 3–4 h in a
humidified chamber at 37 !C in the dark. The plate was
centrifuged, supernatant aspirated, 100 ll/well of DMSO
added, and the absorbance measured at 540 nm. Data
were normalized relative to untreated controls, which
were taken as 100 % survival.
Colony/foci formation assays were used to assess
long-term cell survival. Cells were seeded into 12-well
plates, allowed to attach overnight, and drug treated for
24 h. Attached cells were then trypsinized, counted, and
1,000 cells were plated in triplicate in 6-well plates and
allowed to grow for 8 or 12 days. Cells were fixed with
4 % paraformaldehyde for 15 min with 0.1 % crystal
violet.

Adherent and non-adherent cells were collected, fixed in
ice-cold 70 % ethanol, and kept at 4 !C overnight. Cells
were then stained with 20 lg/ml propidium iodine, 200 lg/
ml RNase A, and 0.1 % Triton X-100 in PBS for 30 min in
the dark at room temperature. Data was acquired on a
FACS Scan or Calibur and analyzed with ModFit software.

RNA interference
Small interfering RNA (siRNA) for Mcl-1 (#sc-35877),
Bcl-xL (#43630), and Control-A (#sc-37007) was purchased from Santa Cruz. Cells were transfected with
RNAiMax (Invitrogen) with a reverse transfection protocol
according to the manufacturer’s protocol. Briefly, siRNA
and RNAiMax were incubated in serum-free RPMI 1640
for at least 20 min at room temperature. After siRNA:
RNAiMax complexes were allowed to form, diluted cells
in full serum media (RPMI 1640 ? 10 % FBS) were added
and the mixture plated out.

Results
Gamma-secretase inhibitors attenuate chemotherapyinduced apoptosis of colon cancer cells
Oxaliplatin is the first line of chemotherapy for colon cancer.
We hypothesized that combining oxaliplatin with GSIs
would enhance chemosensitivity in colon cancer cell lines,
as others have shown using alternative GSIs [36–38].
To explore the role of gamma-secretase inhibition on
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oxaliplatin-induced apoptosis, two colon cancer cell lines—
HCT-116 and SW480—were treated with oxaliplatin in the
absence or presence of MRK-003 (Merck, Inc.), a potent
gamma-secretase inhibitor. Apoptosis was measured by flow
cytometry using either Annexin-V with 7-AAD double
staining or measuring active caspase-3. The combination of
oxaliplatin and MRK-003 resulted in a reduction in apoptosis
by at least 50 % as measured by either Annexin-V and
7-AAD positivity (Fig. 1a) or activated caspase-3 (Fig. 1b)
in both cell lines compared to oxaliplatin alone. To confirm
that the results were likely due to gamma-secretase inhibition
and not an off target effect of MRK-003, the effect of alternative GSIs on apoptosis of oxaliplatin treated cells were
repeated using DAPT, GSI-XII, and GSI-XX (DBZ), widely
used and commercially available GSIs that are structurally
distinct from MRK-003. Both cell lines treated with DAPT
and GSI-XX showed apoptosis rates approximately half that
of oxaliplatin-treated cells (Supplemental Fig. 1a, c). The
gamma-secretase inhibitor GSI-XII showed a slight decrease
in oxaliplatin-induced apoptosis in SW480 but a slight
induction was observed in HCT-116 (Supplemental Fig. 1b).
MRK-003, DAPT, GSI-XII, or GSI-XX alone did not induce
apoptosis in either HCT-116 or SW480 (Fig. 1a, b, Supplemental Fig. 1a–c). We further tested the effect of MRK-003
on oxaliplatin-induced apoptosis in three additional colon
cancer cell lines to determine whether the reduction in
apoptosis was cell line specific. We found greater than 50 %
reduction of apoptosis in oxaliplatin-treated HT-29, HCT15, and Colo205 cells in the presence of MRK-003 (Supplemental Fig. 2). To test if the attenuation of apoptosis was
specific to oxaliplatin, we assessed the effects of gammasecretase inhibition with either irinotecan or etoposide.
Again, we observed a reduction of apoptosis in HCT-116
with MRK-003 in combination with either irinotecan or
etoposide; no difference in apoptosis was observed in
SW480 (Fig. 1c). Taken together, these data suggest that
gamma-secretase inhibition attenuates apoptosis induced by
chemotherapeutic agents in colon cancer.
The combined use of oxaliplatin and MRK-003
increases long-term survival in vitro
We hypothesized the attenuation of apoptosis seen in cells
treated with oxaliplatin and MRK-003 might be due to
increased survival, as measured by MTT assay and cell
cycle analysis. HCT-116 and SW480 were treated for 48 h
with oxaliplatin with or without MRK-003 and survival
was measured by MTT assay. As expected, oxaliplatin
treatment decreased viability by approximately 60 % for
both cell lines; the combination of oxaliplatin and MRK003 showed no difference compared to oxaliplatin alone
(Fig. 2a). MRK-003 alone had no effect on viability
compared to vehicle in either cell line.

Cell cycle analysis showed oxaliplatin induced a G2-M
arrest in HCT-116 that remained unchanged with the
addition of MRK-003; the percentage of cells in G0/G1,
however, increased (21–32 %, respectively) (Fig. 2b).
Oxaliplatin arrested SW480 cells in S phase and no change
was observed with the addition of MRK-003 in the cell
cycle profile (Fig. 2b). MRK-003 alone increased the G0/
G1 fraction from 34 to 48 % in HCT-116.
Colony forming assays are a measure of long-term
survival. Cell death may be mediated through non-apoptotic mechanisms or may be delayed. The combination of
oxaliplatin and MRK-003 remarkably enhanced colony
formation in both HCT-116 and SW480 when compared to
oxaliplatin treated alone (Fig. 2c). Collectively, the data
suggests that GSI enhances the survival of cells treated
with oxaliplatin.
Attenuation of the apoptotic signaling cascade
The mechanisms underlying gamma-secretase inhibition on
oxaliplatin-induced apoptosis was examined by evaluating
changes in the classical apoptotic signaling cascade. Cells
treated with oxaliplatin and MRK-003 blocked cleavage of
PARP (Fig. 3a) and caspase-3 (Fig. 1b) in both HCT116
and SW480 as measured by western blot and flow
cytometry, respectively. Caspase activity can be blocked
through direct interaction with the inhibitor of apoptosis
protein (IAP) family members c-IAP1, c-IAP2 and XIAP,
but no differences in protein levels were detected by
western blot (data not shown). Second, oxaliplatin-induced
cytochrome c release in both HCT-116 and SW480 was
blocked by the addition of MRK-003 (Fig. 3b).
Bax and Bak are the two key pro-apoptotic proteins that
regulate cytochrome c release. Bax and Bak are activated
by conformational changes to promote homo-oligomerization to create pore-like channels responsible for cytochrome c release (reviewed in [39]). The activation of Bax
and Bak can be assessed using conformation specific
antibodies (6A7 for Bax and Ab-1 for Bak) [40]. To
determine if MRK-003 altered the activation of Bax and
Bak in oxaliplatin-treated cells, Bax and Bak were immunoprecipitated with their active conformation specific
antibodies and western blotted. In response to oxaliplatin,
both HCT-116 and SW480 show activation of Bax and
Bak, which was markedly inhibited in the presence of
MRK-003 (Fig. 3c).
Mcl-1 and Bcl-xL levels are elevated
in oxaliplatin?GSI treated cells
The activation of Bax and Bak can be prevented by the
anti-apoptotic Bcl-2 family member proteins Bcl-2,
Bcl-xL, Mcl-1, Bcl-w, and A1 [41]. Gamma-secretase
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Fig. 1 Gamma-secretase inhibition attenuates oxaliplatin-induced
apoptosis. HCT-116 and SW480 cells were treated with 15 lM
(HCT-116) or 30 lM (SW480) oxaliplatin (Oxa) for 48 h in the
absence or presence of 10 lM (HCT-116) or 5 lM (SW480) MRK003 (GSI). Apoptosis rates were measure by flow cytometry following
Annexin-V/7-AAD staining (a) and active caspase-3 labeling (b).

c HCT-116 and SW480 were treated with either 50 lM Etoposide or
50 lM Irinotecan in the absence or presence of 10 lM (HCT-116) or
5 lM (SW480) MRK-003 for 48 h. Apoptosis rates were measured
by flow cytometry following active caspase-3 reactivity. Represented
data are mean ± SEM of three (a, b) or two (c) independent
experiments

inhibition has been shown to regulate protein expression of
the Bcl-2 family members [23, 42]. We tested whether or
not GSI treatment altered total protein levels of Mcl-1 or
Bcl-xL (neither cell line expressed detectable levels of Bcl2, data not shown). Cells treated with MRK-003 alone

increased Mcl-1 protein levels without seemingly affecting
Bcl-xL levels in both HCT-116 and SW480 (Fig. 4). The
combination of oxaliplatin and MRK-003 lead to enhanced
protein levels of both Mcl-1 and Bcl-xL as compared to
oxaliplatin alone in both cell lines.

123

114

Author's personal copy
Apoptosis

120

% Survival
Untreated

Vehicle

GSI

Oxa

100
80
60
40
20
0

Oxa + GSI

Untreated

Vehicle

100
90
80
70
60
50
40
30
20
10
0

G2
S
G0/G1

Untreated

C

GSI

GSI

Oxa

Oxa + GSI

Oxa

G2
S
G0/G1

Untreated

Oxa + GSI

Oxa

100
90
80
70
60
50
40
30
20
10
0
Vehicle

GSI

Oxa

Oxa + GSI

Oxa + GSI

SW480

HCT -116

Vehicle

Vehicle

GSI

SW480

HCT-116

B

% Cells

SW480

HCT-116

120
100
80
60
40
20
0

% Cells

% Survival

A

Fig. 2 Oxaliplatin and MRK-003 increases long-term survival. HCT116 and SW480 cells were treated with 15 lM (HCT-116) or 30 lM
(SW480) Oxa for 48 h in the absence or presence of 10 lM (HCT116) or 5 lM (SW480) MRK-003. After treatment, MTT for viability
(a) or cell cycle analysis (b) was performed. Represented data are

mean ± SEM of three independent experiments. c Colony/Foci
formation assays on HCT-116 and SW480 cells treated with 1 lM
Oxa in the absence or presence of MRK-003 (10 lM for HCT-116,
5 lM for SW480) for 24 h. Results were repeated twice with similar
results

Knockdown or pharmacologic inhibition of Mcl-1 and/
or Bcl-xL restores apoptosis in cells treated
with oxaliplatin and MRK-003

Knockdown of Mcl-1 and Bcl-xL levels were confirmed by
western blot. Reducing the levels of both Bcl-xL and Mcl-1
with low picomolar doses greatly increased oxaliplatininduced apoptosis which was not inhibited with the addition of MRK-003 (Fig. 5c).
To further confirm the role of Mcl-1 and Bcl-xL in mediating the abrogation of oxaliplatin-induced apoptosis by
MRK-003, we used the BH3-peptide mimetic obatoclax
(GX15-070) to broadly antagonize Bcl-2 pro-survival family
members Mcl-1 and Bcl-xL. Apoptosis inhibition associated
with the combination of oxaliplatin and MRK-003 treatment
was reversed with the addition of obatoclax in both HCT-116
(Fig. 6a) and SW480 (Fig. 6b). Of note, the combination of
MRK-003 and obatoclax also resulted in an increase in
apoptosis in HCT-116 (Fig. 6a). Thus, inhibiting Mcl-1 and/or
Bcl-xL through RNA interference or small molecule inhibitor
(obatoclax) lead to a restoration of apoptosis in colon cancer.

To examine whether the MRK-003 induced increase in the
anti-apoptotic proteins Mcl-1 and/or Bcl-xL is responsible
for decreased sensitivity to oxaliplatin treatment, we used
RNAi interference (siRNA) assays to silence Mcl-1 and/or
Bcl-xL. A dose-dependent knockdown of Mcl-1 resulted in
a dose dependent increase in apoptosis in HCT-116 cells
treated with oxaliplatin and MRK-003 but had no effect
with MRK-003 alone as measured by flow cytometry for
active caspase-3 (Fig. 5a). Reduction of Bcl-xL levels in
HCT-116 produced a similar dose dependent increase in
apoptosis in cells treated with both oxaliplatin and MRK003 (Fig. 5b). As expected, reducing levels of Mcl-1
or Bcl-xL lead to increased sensitivity to oxaliplatin.
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Discussion
In this study, we report that the combination of the gammasecretase inhibitor MRK-003 with oxaliplatin elicited
potent chemoresistance in colon cancer cells by greatly
decreasing apoptosis and leading to increased long-term
survival. We showed the combination of oxaliplatin and
MRK-003 reduced apoptosis in HCT-116, SW480, HT-15,
HT-29, and Colo205 colon cancer cell lines by at least half.
The reduction in apoptosis could be replicated using
alternative GSIs (DAPT and GSI-XX) in HCT-116 and
SW480. GSI-XII, a fourth GSI used in this study, slightly
increased apoptosis by 10 % in HCT-116 and only
decreased apoptosis by approximately 7 % in SW480.
None of the four GSIs used in this study elicited apoptosis
by themselves. When MRK-003 was combined with other

chemotherapeutic agents (etoposide and irinotecan),
decreased apoptosis was also seen in HCT-116. MRK-003,
however, had no effect on apoptosis of etoposide- or irinotecan-treated SW480 cells, a finding reported elsewhere
using DAPT in combination with various chemotherapeutic
agents [38]. These data suggest that the effects seen are not
cell-context specific, mediated by gamma-secretase inhibition (not an off-target effect), and not unique to oxaliplatin treatment. We observed no change in viability in
oxaliplatin-treated cells with or without MRK-003 in either
HCT-116 or SW480. Cell cycle analysis showed a slight
increase in G0/G1 arrest with the addition of MRK-003 in
oxaliplatin-treated HCT-116 cells alone (no change was
observed in SW480). These data do not account for the
reduction in apoptosis seen with MRK-003 treatment.
However, to further support the decrease in apoptosis
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Fig. 4 MRK-003 increases protein expression of Mcl-1 and Bcl-xL.
HCT-116 and SW480 cells were treated with 15 lM (HCT-116) or
30 lM (SW480) for 48 h in the absence or presence of 10 lM (HCT116) or 5 lM (SW480) MRK-003. Total levels of Mcl-1 and Bcl-xL
were assessed by immunoblotting. Beta-actin was used as a protein
loading control

observed in oxaliplatin and MRK-003 treated cell, longterm survival assays showed increased cell survival in
combination treatment compared to oxaliplatin alone.
We identified increased protein levels of the anti-apoptotic
Bcl-2 family members Mcl-1 and Bcl-xL in response to
MRK-003 as pivotal players responsible for decreased oxaliplatin-induced apoptosis, leading to a reduction of Bax and
Bak activation and downstream suppression of the apoptotic
cascade (cytochrome c release, caspase-3 cleavage, and
PARP cleavage). Restoration of apoptosis was achieved by
blocking Mcl-1 and/or Bcl-xL through RNA interference or
the Mcl-1/Bcl-xL/Bcl-2 antagonist obatoclax. Knockdown of
Mcl-1 and/or Bcl-xL, however, did not induce apoptosis upon
GSI treatment alone but the combination of GSI and obatoclax did in HCT-116. From these data, we conclude that
increased protein levels of Mcl-1 and/or Bcl-xL are responsible for the attenuation of oxaliplatin-induced apoptosis
observed upon MRK-003 treatment.
Several studies have highlighted the role of Notch signaling in the regulation of Mcl-1 and Bcl-xL. Mcl-1 levels
are decreased by blocking the Notch pathway via a GSI [42]
or with small-interfering RNA [43] and increased by overexpression of NICD [42]. GSIs have been shown to increase
Noxa, a pro-survival BH3-only protein that promotes Mcl-1
degradation [44, 45]. Likewise, blocking Notch signaling
can decrease Bcl-xL levels [27, 44]. In contrast, our data
shows increased protein levels of Mcl-1 and Bcl-xL upon
GSI treatment. This phenomena has been replicated by Liu
et al. [46] in T-ALL cell lines when examining the effect of
gamma-secretase inhibition on chemosensitivity. One subset
of cells exhibited enhancement of apoptosis while another
subset showed resistance via upregulation of Bcl-xL. The
mechanism by which this occurs is still not well defined.

Our data also conflicts with other reports in the literature showing synergism between cytotoxic agents and
GSIs in colon cancer cell lines. One study showed that
blocking Notch-1 signaling using GSI34 (a novel gammasecretase inhibitor) lead to an enhancement of oxaliplatin
sensitivity [36]. Alternatively, DAPT sensitized colon
cancer cell lines SW480 and DLD-1 to paclitaxel only but
not 5-FU, camptothecin, TRAIL, or cisplatin [38]. A third
group tested the effects of GSI-XX (DBZ), another GSI, in
combination with platinum compounds (cisplatin, carboplatin, and oxaliplatin) on a panel of 20 human colon
cancer cell lines [37]. GSI-XX alone had no effect on cell
survival and, in combination with cisplatin, only a subset
exhibited some degree of increased cell death; a few cell
lines sensitive to the combination of cisplatin and GSI-XX
showed no effect with oxaliplatin or carboplatin. In our
hands, gamma-secretase inhibition using MRK-003,
DAPT, or GSI-XX abrogated oxaliplatin-induced apoptosis via increased Mcl-1 and/or Bcl-xL protein levels, as
seen by Liu et al. [46]. The pleotropic nature of gammasecretase inhibition on chemotherapy-induced apoptosis is
not well understood. It likely could be a reflection of
complex context-dependent signaling downstream of the
Notch pathway, and thus may only be of clinical utility to
a particular (as yet undefined) subtype of colorectal
cancer.
The observed effects of MRK-003, DAPT, and GSI-XX
on attenuating chemotherapy-induced apoptosis may not be
caused by Notch inhibition but rather differential targeting
of other known gamma-secretase substrates. Gammasecretase primarily catalyzes the intramembranous cleavage of Notch and APP. However, it has also been shown to
target at least a dozen known type I transmembrane proteins, including E-cadherin, ErbB4, CD44, and c-Met, but
their mechanism and function is not well studied (for
review, see [47]). Also, the specificity of GSIs for different
substrates may drive the discrepancies found in the literature, thus it will be important to understand the biochemical differences between specific GSIs, particularly since
we showed that GSI-XII did not have the same effect as the
other three GSIs. While we used four commercially
available inhibitors known to block both Notch cleavage
and activity as well as induce apoptosis in multiple tumor
cell lines, we cannot rule out the possibility that these GSIs
may also indirectly target other molecular pathways, such
as pro-apoptotic signaling pathways, which may outweigh
or antagonize any pro-apoptotic effects conferred by
reduced Notch signaling in colon cancer cells. Therefore,
the contribution of single, combinatorial, or complete
ablation of all four Notch receptors on chemosensitivity is
needed to address these concerns. The newly emerging
neutralizing antibodies to individual Notch receptors will
surely help to answer this question.
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Fig. 5 Knockdown of Mcl-1 and/or Bcl-xL rescues MRK-003
attenuation of oxaliplatin-induced apoptosis. a HCT-116 was transfected with increasing amounts of Mcl-1 siRNA as indicated for 24 h.
Cells were then treated with 15 lM Oxa in the absence or presence of
10 lM MRK-003 for 48 h. Western blot shows efficiency of Mcl-1
knockdown. b HCT-116 was transfected with increasing amounts of
Bcl-xL siRNA as indicated for 24 h. Cells were then treated with
15 lM Oxa in the absence or presence of 10 lM MRK-003 for 48 h.

Western blot shows efficiency of Bcl-xL knockdown. c HCT-116 was
transfected with 250 pM Mcl-1 and 25 pM Bcl-xL siRNA as
indicated for 24 h. Cells were then treated with 15 lM Oxa in the
absence or presence of 10 lM MRK-003 for 48 h. Apoptosis rates
were measure by flow cytometry following active caspase-3 reactivity. Represented data are mean ± SEM of two independent
experiments

Standard chemotherapy approaches may need to be
modified to include other novel inhibitors. Despite the
apparent discrepancies of gamma-secretase inhibition on
chemosensitivity, we were able to restore the attenuation of
oxaliplatin-induced apoptosis seen with MRK-003 by
antagonizing Mcl-1 and/or Bcl-xL. Combining GSIs and

chemotherapy with an anti-apoptotic Bcl-2 family member
agonist like obatoclax may be a valid therapeutic approach.
We also found enhanced apoptosis with MRK-003 and
obatoclax combined. Previous studies have shown sensitization with the combination of GSIs and the BH3 mimetic
ABT-737 (antagonizes Bcl-2/Bcl-xL/Bcl-w but not Mcl-1
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Fig. 6 Obatoclax rescues MRK-003 attenuation of Oxaliplatininduced apoptosis. a HCT-116 was treated with 15 lM Oxa in the
absence or presence of 10 lM MRK-003 and/or 75 nM obatoclax
(Obx) for 48 h. b SW480 was treated with 30 lM Oxa in the absence

or presence of 5 lM MRK-003 and/or 25 nM obatoclax for 48 h.
Apoptosis rates were measured by flow cytometry following active
caspase-3 reactivity. Represented data are mean ± SEM of at least
two independent experiments

[48]) in GSI-sensitive cell lines where GSI alone increased
Noxa levels, leading to subsequent Mcl-1 degradation [45,
49]. Our data shows MRK-003 synergism with obatoclax in
GSI-resistant colon cancer cell lines where GSI alone
increases Mcl-1 and Bcl-xL levels. Therefore, combining
GSIs with other targeted therapeutics instead of chemotherapy may be a more effective strategy in the treatment
of colorectal cancer.
To our knowledge, the only published Phase II clinical
trial studying the efficacy of gamma-secretase inhibitor—
RO4929097—monotherapy in metastatic colorectal cancer
patients demonstrated no antitumor effects [50]. Nevertheless, there are multiple clinical trials investigating
mono- and combination therapies involving GSIs in a wide
variety of tumors (www.clinicaltrials.gov). The results
posed here do not diminish the potential use of GSIs in a
clinical setting but rather suggest caution when developing
drug combinations. First, further detailed mechanistic

studies looking at the biochemical differences in substrate
specificity and potential off-target effects of the many
available GSIs are needed. Also, the effects of gammasecretase inhibition in relation to cell context and interactions with signaling pathways needs further clarification as
there are clear indications that GSIs can have opposing
effects even in same tumor types. Third, the potential still
exists for using GSIs in combination with other therapeutic
agents to elicit anti-tumorigenic responses. Our results
provide a cautionary tale for broad application of GSIs.
Understanding the actions of this drug when used in
combination with standard chemotherapy and/or targeted
therapies will provide greater knowledge of its potential
use for a personalized approach to cancer treatment.
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